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Abstract 
 
Skeletal muscle provides an organism with a means of reacting to its environments. It is 
a complex and versatile tissue that is capable of change under a variety of conditions. 
For example extensive literature has shown muscle transformation from slow-to-fast by 
decreased motor nerve activity, hypogravity, physical inactivity and in diseased states. 
Similarly muscle transformation from fast-to-slow can be evoked by increased muscle 
nerve activity or exercise. The multitude of protein changes that has been identified by 
muscle transformation indicates it is a complex process that can change a wide variety 
of the muscle tissues architecture, metabolism and function.  
Proteomic profiling of two very different diseased states has allowed the identification 
of muscle transformation occurring in opposite directions. Myotonia a common feature 
found in myotonic dystrophies is characterized by skeletal muscle membrane 
hyperexcitability. Proteomic profiling was carried out on three independent 
spontaneous mutant mice and allowed us to compare secondary effects of 
hyperexcitabilty on skeletal muscle. Severly myotonic mice MTO and ADR displayed a 
muscle transformation from fast-to-slow. The more mildly affected MTO*5J mutant 
showed slight changes in proteins associated with fast and slow muscle.  
In comparison to the myotonic diseased state we carried out proteomic profiling of 
skeletal muscle tissue from the Wobbler mouse; an animal model of motor neuron 
degeneration. In contrast to myotonia the WR protein profile displayed a slow-to-fast 
muscle transformation.  
The detailed MS-based analysis of diseased skeletal muscle has shown that proteomics 
is highly suitable to determine change in the isoform expression pattern of muscle 
proteins. Identified proteins can be used as potential factors for the establishment of 
comprehensive biomarker signature of myotonic and motor neuron diseases. 
 
 
 
 
  1 
1. Introduction 
 
1.1 Muscle Biology 
Muscle tissue is defined by its ability to use chemical energy to produce force and movement. 
The ability to move provides an organism with a means of reacting to the environment. 
Muscle tissue can be categorized into four distinct classes: skeletal muscle, cardiac muscle, 
smooth muscle and myoepithelial cells, all differing in function and location. Cardiac muscle 
forms the walls of the heart and is striated like skeletal muscle. The striations found in cardiac 
and skeletal muscle are due to the arrangement of contractile proteins, and for this reason 
cardiac and skeletal muscle have similar mechanisms of contraction. Skeletal muscle 
functions in short bursts of contraction and its contraction is voluntary whereas cardiac, 
smooth and myoepithelial muscle is involuntary (i.e. not controlled by the somatic nervous 
system). Cardiac muscle has continuous activity and is resistant to fatigue due to its high 
concentration of mitochondria. Myoepithelial muscle can be found in areas of the body such 
as the glands and eye, whereas skeletal muscle is attached to the bones of the skeleton via 
tendons, and is found throughout the body.  
 
1.2 Skeletal Muscle 
1.2.1 Skeletal Muscle Formation 
Skeletal muscle is formed during embryonic development by a process called myogenesis. 
Transcription factors such as MyoD, stimulate indeterminate stem cells to become 
determinate muscle cells (Berkes and Tapscott 2005). These determinate muscle cells undergo 
myogenesis in order to develop into mature muscle cells. Mature muscle cells develop into 
larger cells called myoblasts that fuse together forming myotubes. These myotubes will 
eventually develop into long strands of muscle fibers. Muscle fibers are arranged 
longitudinally and are bound together by connective tissue. It is these fibers that make up 
mature muscle.  
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1.2.2 Skeletal Muscle Structure and Function 
Skeletal muscle fibers are made up of many myofibrils that are arranged longitudinally and 
run along the axis of each fiber. Each myofibril contains sarcomeres (see figure 1.1) that are 
made of two types of filaments, thick and thin filaments. Thin filaments are made up of two 
actin strands, which twist together to form an alpha helix, bound to this helix are the proteins 
tropomyosin and troponin. Tropomyosin lies in the grooves of the actin helix with one 
troponin complex associated with each tropomyosin molecule (Squire and Morris 1998). The 
troponin complex is made up of troponin C (TnC) that is the binding site for calcium ions 
(Ca
2+
), troponin I (TnI) that inhibits actin-myosin binding and troponin T (TnT) that binds 
strongly to tropomyosin. Thick filaments are made up of myosin. A myosin molecule is 
composed of 6 polypeptides: 2 heavy chains (MHC) and 4 light chains (MLC) (2 regulatory 
and 2 alkali) (Clark et al. 2002). A regulatory and an alkali light chain are associated with 
each heavy chain. The MLCs make up the myosin heads of the thick filament and are called 
subfragment 1 (S1) and are connected to the alpha-helix tail made of MHCs. Thin filaments 
surround each thick filament and it is this arrangement that gives muscle cells its striated 
appearance. Muscle force is produced when projecting myosin heads on the myosin molecule 
interact with adjacent actin filaments.  
  3 
 
 
 
Figure 1.1 Sarcomere structure 
Shown is the simplified structure of the sarcomere. The sarcomere is the single contractile 
unit of skeletal muscle. The Z line is made up of actinin and act to anchor the thin filaments. 
The A band is a condensed area at the centre of the sarcomere and consists of the thick 
filaments and overlapping areas of thin filaments. The I band consists of the non-overlapping 
portions of the thin filaments and the Z line. Adapted from Huxley (2004).  
 
Skeletal muscle contraction begins at the motor cortex of the brain and travels through the 
somatic nervous system as an electrical signal. When this signal reaches a motor neuron that 
ends at a muscle fiber it comes to a neuromuscular junction (shown in Figure 1.2). At the 
neuromuscular junction the electrical signal is converted to a chemical one in the form of 
acetylcholine (ACh) in order to allow the signal to cross the gap (synapse) between the motor 
neuron and the muscle fiber. ACh is released from the terminus of the motor neuron, crosses 
the synapse and binds to post-synaptic acetylcholine receptors (AChR) located on the muscle 
membrane. Activation of AChR causes localized depolarization (Farley et al. 1977) resulting 
in the opening of sodium channels. As sodium ions (Na
+
) enter the cytosol the sarcolemma 
becomes depolarized (Hodgkin et al. 1960) and an action potential is started. The action 
potential travels along the sarcolemma and enters into the transverse tubules (T-tubules), 
which are invaginations of the sarcolemma.  
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Figure 1.2 Structure and molecular architecture of the neuromuscular junction. 
Shown is the progressive enlargement of the neuromuscular junction. The neurotransmitter 
acetylcholine (Ach) is released from the axon and diffuses across the synapse and binds to 
acetylcholine receptors (AChR) on the sarcolemma that results in the start of an action 
potential along the sarcolemma. Muscle thyrosine kinase (MuSK) functions to organize AchR 
clustering at the neuromuscular junction in order to maintain muscle function. Redrawn from 
Shigemoto et al. 2010.  
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Depolarization traveling in the T-tubules activates the voltage sensing alpha 1 subunit of the 
Dihydropyridine receptor (DHPR) resulting in a conformational change in the protein 
allowing its II-III loop domain to directly interact with the intracellular ryanodine receptor 
(RyR) (Proenza et al. 2002) of the sarcoplasmic reticulum (SR). This interaction allows RyR 
to open its calcium channels allowing the flux of calcium ions (Ca
2+
) into the cytoplasm of the 
muscle cell. Cytosolic Ca
2+
 then binds to TnC  (shown in Figure 1.3) resulting in a 
conformational change in the troponin complex. TnI no longer inhibits the actin-myosin 
binding. In the presence of ATP, the myosin head on the thick filament binds to the myosin 
binding site on the actin molecule, ATP is broken down to ADP and Pi, the myosin head 
releases and moves onward to the next actin molecule along the thin filament. Myosin heads 
of the thick filaments walk toward the ends of the thin filaments thus shortening the 
sarcomere. This process of movement, attach and release is called cross-bridge cycling 
(Huxley et al. 1954). This is repeated until there is a lack of Ca
2+
 or ATP. For muscle 
relaxation, chloride and potassium channels are activated by depolarization of the 
sarcolemma. Once activated chloride ions (Cl
-
) flood into the cell and potassium ions (K
+
) 
move out of the cell. The movement of Cl
-
 into the cell and K
+
 out of the cell function to 
repolarise the sarcolemma. Membrane repolarisation results in the disassembly of the DHPR-
RyR interaction leading to the energy-dependent re-uptake of Ca
2+
 into the lumen of the SR 
by the sarcoplasmic/endoplasmic reticulum ATPase (SERCA). The lack of cytoplasmic Ca
2+
 
causes the calcium ions bound to troponin to be released and tropomyosin returns to its 
normal conformation, preventing any cross bridges from being formed, and the muscle 
relaxes. 
 It is critical that the myosin heads of the thick filament operate with low processitivity such 
that they are tightly bound to the actin of the thin filament for a short amount of time i.e. one 
cycle of ATPase so that they do not hold each other back. This rapid shortening of thousands 
of sarcomeres lying end-to-end in each myofibril results in skeletal muscles ability to contract 
rapidly and is called the sliding filament theory. It is important to note that since sarcomere 
shortening is due to each filament sliding past each other and not due to a change in length of 
the filament. Accessory proteins in the sarcomere enable uniformity in filament organization, 
length and spacing and thus play a huge role in muscle contraction.  
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Figure 1.3 Structure of thin filament and thin filaments 
Shown is the structure of the thin filaments (A) with actin and its regulatory proteins troponin 
and tropomyosin. The thick filament made of myosin molecule (B) is also shown. Adapted 
from Squire and Morris 1998. 
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1.2.3 Skeletal Muscle Fibers 
Skeletal muscle is a complex, versatile tissue composed of a large variety of functionally 
diverse fiber types. The properties of individual muscles largely depend on the combination 
of the individual properties of their different fiber types and their proportions. The earliest 
classification of fiber types began when French anatomist Louis Antoine Ranvier in 1873 
observed that some muscles of the rabbit were redder in color and contracted in a slower 
manner compared to paler muscles. This observation formed the basis for the classical 
terminology of red (slow-twitch) or type I fibers and white (fast-twitch) or type II fibers.  In 
humans a further subdivision was made whereby fast-twitch fibers were either more aerobic 
using oxidative metabolism Type IIA or anaerobic using glycolytic metabolism Type IIB. 
This allowed muscle fibers to be classified in terms of their contractile and metabolic 
properties. Today muscle fibers are classified by three different methods: histochemical 
staining for myofibrillar ATPase (mATPase), myosin heavy chain (MHC) isoform 
identification and biochemical identification of metabolic enzymes (Staron and Pette 2000). 
 
1.2.4 Fiber Classification 
1.2.4.1 Fiber Metabolism 
Muscle tissue requires pathways for energy metabolism that can provide energy during long 
periods of slightly increased energy consumption and short bursts of high-energy 
consumption. Energy is mainly consumed by the molecular motors during muscle contraction 
i.e. myosin heads and ion pumps (Westerblad et al. 2010). The energy required for muscle 
contraction depends on the type of contraction, whether it is short repeated contraction or long 
continuous contraction. In skeletal muscle, energy for contraction is supplied by adenosine 
triphosphate (ATP) via anaerobic glycolysis, the phosphocreatine shuttle and oxidative 
phosphorylation (Ohlendieck, 2010).  
 Glycogen breakdown is regulated by glycogen phosphorylase. Glycogen phosphorylase 
releases glucose residues from glycogen. Glucose enters the glycolysis pathway were it is 
ultimately converted to pyruvate with the production of ATP. Fast twitch fibers mainly use 
glycolysis for their energy metabolism (Peter et al. 1972). During intense exercise lactate 
dehydrogenase turns NADH +H
+
 +pyruvate into lactate +NAD
+
. This reaction occurs to 
regenerate NAD
+
 that is consumed during glycolysis so that the muscle can maintain the 
glycolytic pathway (Katz et al. 1988).  
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 Anaerobic metabolism is also dominated by degradation of phosphocreatine. The degradation 
of phosphocreatine (PCr) is catalyzed by the enzyme creatine kinase. Creatine kinase breaks 
down PCr + ADP to creatine + ATP.  
 Oxidative metabolism of carbohydrates and lipids are the dominating-ATP producing 
systems during aerobic metabolism. The major carbohydrate used for oxidative metabolism is 
glucose. In the presence of oxygen, glucose + oxygen are broken down to release carbon 
dioxide + water. This process takes place within the mitochondria through the Krebs cycle 
and oxidative phosphorylation. The substrate for lipid metabolism is free fatty acids obtained 
from triglyceride stored in muscle. Also amino acids can be an additional substrate for aerobic 
metabolism. Amino acids can be derived from muscle protein degradation. Slow-twitch fibers 
gain their energy needs mostly through oxidative metabolism. 
 
1.2.4.2 Myosin Heavy Chain isoform 
As previously stated myosin is a hexameric protein composed of heavy and light chains. One 
of the best ways to characterize muscle fibers types is based on myosin heavy chain (MHC) 
complement. A total of eleven MHC isoforms have been identified to date (Pette and Staron 
2000). Some MHC isoforms are expressed in a specific manner; for example, MHC 
embryonic (MHCemb) is only expressed in adult extraocular muscles (Pette and Staron 2000). 
Others are widely distributed throughout skeletal muscle. Skeletal muscle isoforms of MHC 
include: MHCI, MHCIIa, MHCIId and MHCIIb. Shown in Table 1.1 are the pure fibers that 
only express one MHC isoform and include slow type I, and three fast types type IIA, type 
IID and type IIB (Pette and Staron 2000). Muscles in humans and other large mammals do not 
express MHCIIb therefore fibers that were classified as type IIB in human muscle have been 
renamed type IIX and express MHCIIx. MHCIId and fiber type IID found in small mammals 
like the rat are considered to be equivalent to MHCIIx and fiber type IIX respectively in 
human muscle (Pette and Staron, 1990; Schiaffino and Reggiani, 1994, 1996). Co-expression 
of specific pairs of MHC isoforms results in the formation of hybrid fibers (shown in Table 
1.1). Hybrid fibers bridge the gap between pure fibers in muscle tissue. 
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Table 1.1 Muscle fiber types 
 Shown are the different MHC isoforms that make up both pure muscle fibers and hybrid 
muscle fibers along with examplar tissues. Slow fibers are found in postural muscle tissue e.g. 
soleus muscle where as fast fibers are found in muscle tissue that functions in phasic 
contraction. (Staron and Pette 2000). 
 
1.2.4.3 Contractile Activity 
Skeletal muscle fibers show characteristic mechanical properties including shortening 
velocities and ATPase activity. Correlations between contractile properties and myosin 
isoforms were initially demonstrated by the work of Bárány in 1967 (Bárány 1967). More 
refined experiments have shown correlations between MHC-based fiber types and maximum 
shortening velocities i.e. shortening of the sarcomere during contraction (Bottinelli et al. 
1991). Velocity is lowest in type I fibers and fastest in type IIB. Histochemical staining for 
mATPase shows the differences in the pH stability of mATPase activity with fibers being 
separated based solely on staining intensities (Weiss et al. 1999). The slowest fiber type I 
stains light whereas the fastest fiber type IIB stain more (Staron 1997). As mATPase resides 
PURE FIBERS MYOSIN ISOFORM TISSUE 
Slow type I MHCIb Soleus muscle 
Fast type IIA MHCIa Diaphragm 
Fast type IID/IIX MHCIId/IIx Tibialis Anterior 
Fast type IIB MHCIIb EDL 
HYBRID FIBERS   
Type I/IIA MHCI>MHCIIa Vastus Lateralis 
(women) 
Type IIA/I MHCIIa>MHCIb Vastus Lateralis 
(men) 
Type IIA/IID MHCIIa>MHCIId Tibialis Posterior 
Type IID/IIA MHCIId>MHCIIa Tibialis Anterior 
Type IID/IIB MHCIId>MHCIIb Gastrocnemius 
Type IIB/IID MHCIIb>MHCIId EDL 
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in the heavy chain of myosin molecule in muscle (Weiss et al. 1999) histochemical staining of 
mATPase correlates with the type of MHC isoform expressed by the muscle fiber. 
 
1.2.4.4 Other Proteins 
As well as specific MHC isoform expression muscle fibers also have fiber type-specific 
programs of gene expression for many other muscle proteins. Fiber type-specific isoforms 
exist for the myosin light chain (MLC) of the myosin molecule, the three troponin units, 
tropomyosin, a-actinin and Ca
2+
-regulatory proteins. Not only are there differences in isoform 
expression between muscle fibers, there exists certain proteins that are only expressed in 
certain muscle fibers. For example, in rodents the Ca
2+
-binding protein parvalbumin is 
expressed in type II fibers but not in type I fibers (Celio and Heizmann 1982). Parvalbumin is 
a calcium binding protein and is thought to function in relaxation of fast-twitch fibers by 
acting as a temporary Ca
2+
 buffer (Racay et al. 2006). Chen and colleagues (2001) found 
parvalbumin deficiency in fast-twitch fibers results in the fibers becoming more resistant to 
fatigue with the ability to sustain muscle activity for prolonged periods indicative of slow-
twitch fibers. 
  11 
1.2.5 Fiber Type Transitions 
Muscle fibers are dynamic structures that are capable of change under a variety of 
circumstances for example, altered neuromuscular activity, mechanical unloading or loading, 
altered hormonal profiles, systemic diseases or during aging. Fiber transitions generally 
follow a scheme of either fast-to-slow or slow-to-fast and are determined by changes in MHC 
isoform expression shown below: 
 
 
 
 
 
 
These MHC isoform transitions are related to energy cost of force production (Bottinelli et al. 
1994a) and also differences in the ATP phosphorylations in fast and slow muscle fibers 
(Conjard et al. 1998). Extensive literature on muscle plasticity show fast-to-slow fiber 
transformation is evoked by increased motor nerve activity, cross-innervation, electrical 
pacing, or excercise. Slow-to-fast fiber transformation occurs as a consequence of decreased 
motor nerve activity, cross-innervation, certain diseased states, hypogravity, or physical 
inactivity (Neufer et al. 1996).  
 The importance of neuromuscular activity on muscle fiber phenotype has been demonstrated 
by numerous denervation experiments for example, by Jakubiec-Puka and colleagues (1990). 
In the absence of innervation slow muscles become faster and fast muscles become slower. 
Therefore denervation causes decreases in concentrations of slow MHC isoforms in slow 
muscles and a similar decrease of fast MHC isoforms in fast muscles (Jakubiec-Puka et al. 
1990). In 1959 Buller and co-workers carried out a series of cross-reinnervation experiments, 
whereby fast muscles were reinnervated with a slow nerve and slow muscles were innervated 
with a fast nerve. The results showed that the fast muscles turned slow and the slow muscles 
turned fast. These experiments showed the important of innervation in the establishment of 
specific muscle phenotypes. The changes in phenotype followng cross-reinnervation are 
primarly due to specific neural impulses delivered to the muscle. Later two protocols for 
eletrostimulation elvolved to mimic the firing patterns delivered to muscle from fast and slow 
motor neurons. Salmons and Vrbová in 1969 used chronic low-frequency stimulation (CLFS) 
to mimic the impulse patterns of slow motor neuron and Lömo and co-workers in 1974 used 
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phasic high-frequency stimulation to mimic the pattern normally delivered to fast-twitch 
muscles by the fast motor neuron. CLFS mimics the impulse pattern by prolonging 
contraction and relaxation times of the fast twitch muscle (Pette 2001). CFLS of fast-twitch 
muscle induces a shift in MHC isoform from MHCIIb to MHCI. Up to a 60% increase in 
hybrid fibers is also seen during this muscle transformation (Pette 2001). Studies using CFLS 
have shown it affects all functional elements of the muscle fiber including the major 
myofibrillar proteins, mitochondrial and cytosolic enzymes involved in energy metabolism 
(Berchtold et al. 2000) and variuos proteins of the sarcoplasmic reticulum (Ohlendieck et al. 
1999).  
CFLS can also be applied to slow-twitch muscle but will have no effect unless the muscle is 
denervated whereby the slow phenotype will be maintained by direct low-frequency 
stimulation (Pette et al. 1975).  
Phasic high-frequency stimulation of denervated slow muscles shows a slow-to-fast transition 
in myosin isoforms (Gorza et al. 1988). However the slow-to-fast transition is never complete 
even following days of stimulation whereby significant amounts of slow myosin still remain 
(Bacou et al. 1996). 
 Meachanical unloading of muscles has been studied using models of immobilisation, limb 
suspension and microgravity. Unloading of slow muscles via these methods induces a slow-
to-fast transformation (Staron et al. 1998), whereas unloading of fast muscles induces less 
obvious changes (Jänkälä et al. 1997). Mechanical overloading is obtained by the method 
stretch overload whereby muscles are immobilised in a lengthened position. This has been 
shown to increase slow fibers in immobilised fast muscle (Pattullo et al. 1992). Functional 
overload has also been used in the compensatory hypertrophy model (Goldberg, 1967). 
Similar to stretch overload it showed an increase in slow fibers and increases in MHCI at the 
protein level and mRNA level (Gregory et al. 1986, 1990). 
 Thyroid hormones have an immense effect on muscle fiber phenotype. Generally 
hypothroidism causes fast-to-slow transitions (Fitts et al. 1980) whereas hypertyroidism 
causes a slow-to-fast transition (Pette and Staron 1997). Low levels of thyroid hormones 
cause a fast-to-slow transition in MHC isoform expression: MHCIIb-MHCIId-MHCIIa-
MHCI, whereas high levels of thyroid hormones causes a slow-to-fast MHC isoform 
expression: MHCI-MHCIIa-MHCIId-MHCIIb (Caiozzo et al. 1992). Another hormone that 
can have a significant effect on fiber type  is testosterone. Studies have shown that 
testosterone can effect the temporalis muscle in the guinea pig (Gutmann and Hanzlíková 
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1970) and the laryngeal muscle fibers of the frog (Catz et al. 1995). Expression of the 
largngeal specific MHC “LM” was shown to be decreased with the removal of testis from the 
male and incresed in females when subjected to exogenous androgen. 
 Muscle aging has severe effects on muscle mass. Numerous studies have shown that there is 
an age-related change in fiber type and MHC isoform expression. In skeletal muscles of the 
rat Gannon and colleagues (2009) have shown a drastic reduction in MHC fast expression in 
aged muscle. As extrinsic and intrinsic factors play a role in muscle aging it is difficult to say 
whether these changes are primary or secondary events in aging muscle. 
 
1.2.6 Mechanisms of Fiber Transitions 
As discussed muscle fiber transitions can occur under a variety of conditions and include 
changes in MHC isoforms, sarcoplasmic reticulum proteins and metabolic proteins. These 
changes in protein isoforms and their expression are controlled by transcription, translation 
and protein degradation. A change in gene transcription and translation effect gene expression 
and repression whereas proteolysis plays a role in the degradation of proteins.  Skeletal 
muscle fiber phenotype is regulated by several independent signalling pathways. These 
include pathways involved in Ras/mitogen-activated protein kinase (MAPK), calcineurin, 
calcium/calmodulin-dependent protein kinase IV and the peroxisome proliferator g 
coactivator 1 (PGC-1). 
 The Ras pathway has been shown to control differentiation of muscle fiber types by nerve 
activity (Muriga et al. 2000). Muriga and coworkers (2000) showed that activated MAPK 
pathway is sufficient to drive a slow myosin gene programme in denervated regenerating 
soleus muscle. Also slow motor neurons cannot induce slow myosin when Ras/MAPK 
signalling is inhibited. 
Calcineurin is a Ca
2+
/calmodulin-acitvated phosphatase. Binding of Ca
2+
 to a 
calmodulin/calcineurin complex stimulates serine/threonine phospatase activity of 
calcineurin. The major substrate for calcineurin is a family of nuclear factor of activated t 
cells (NFAT) transcription factors. Dephosphorylation of NFATs by calcineurin promotes 
their translocation to the nucleus where they bind to DNA and stimulate transcription of target 
genes. Chin and coworkers in 1998 described how calcineurin relates motor neuron activity 
control programs of gene expression that define fast and slow subtypes of skeletal fibers. 
They investigated how tonic motor neuron activity characterisitc of those innervating slow 
muscles sustains Ca
2+
 concentration at sufficient levels to activate the calcineurin-NFAT 
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pathway. Whereas phasic firing of motor nerve activity characteristic of those innervating fast 
muscles are of insufficient duration to maintain calcineurin in the active state and so NFAT 
proteins remain phosphorylated and do not enter the nucleus (Chin et al. 1998). When NFAT 
proteins do not enter the nucleus the slow-specific program of proteins is down regulated and 
genes encoding the fast fiber-specific proteins are transcribed. McCullagh and coworkers in 
2004 described how NFAT acts as a sensor selectively responsive to  slow patterns of nerve 
electrical activity and NFAT controls the nerve activity-dependent induction of slow gene 
program during muscle regeneration and maintenance of the slow phenotype in adult skeletal 
muscle. These studies support the idea that calcineurin-dependent signalling is an important 
mechanism to muscle transformations. 
 PGC1 is a transcriptional co-activator of nuclear receptors involved in the regulation of  a 
number of mitochondrial genes that are involved in oxidative metabolism (Lin et al. 2002). 
Increased expression of mitochondrial genes may be related to increased oxidative 
metabolism that is characteristic of slow-twitch fibers.  
 Peroxisome proliferator-activated receptor d (PPARd)-mediated transcriptional pathway is 
involved in the regulation of the skeletal muscle phenotype (Wang et al. 2004). Wang and 
coworkers found that mice with activated PPARd display an increase in oxidative enzymes 
and increased proportion of slow-type fibers.  
 Together these pathways form the basis of a signalling network that controls skeletal muscle 
fiber-type transformation and metabolic profiles. 
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1.3 Myotonia 
Skeletal muscle contraction requires the participation of ion channels in the spreading of an 
excitatory signal from the endplate region  along the surface membrane, and coupling this 
signal in T-tubules to the release of Ca
2+
 from the sarcoplasmic reticulum. Hyperexcitabilty of 
the sarcolemma due to muscle action potentials in response to a single input at the 
neuromuscular junction results in abnormally sustained muscle contraction and is termed 
Myotonia. 
Myotonia is a symptom of myotonic disorders and is characterised as a muscle 
hyperexcitabiltiy or a delay in muscle relaxation. Myotonic disorders can be classified into 
two groups: myotonic dystrophies and nondystrophic myotonias. The myotonic dystrophies 
(DM) are dominantly inherited disorders (Mankodi 2008) and are classified into three groups: 
DM1, DM2 and DM3. Myotonia is the most common symptom but not the most serious 
complication of DM and it is unknown to what extent myotonia contributes to the dystrophic 
process (Wheeler 2008). 
 
1.3.1 Non Dystrophic Myotonias 
Non dystrophic myotonias are pure skeletal muscle disorders whereas dystrophic myotonias 
can effect multiple tissues. The pure skeletal muscle disorders can be subdivided into sodium 
channel myotonias and chloride channel myotonias. Both are due to mutations in voltage-
gated sodium or chloride channel genes that are expressed exclusively in skeletal muscle. 
Mutations in the gene encoding the muscle N
+
-channel are associated with paramyotonia 
congenita, potassium-sensitive myotonia and hyperkalemic periodic paralysis with myotonia. 
In contrast, nondystrophic chloride channelopathies are responsible for myotonia congenita, 
recessive Becker myotonia and dominant Thomsen myotonia. Mutations in these two 
different genes underlie hereditary pure myotonias (Pusch 2002). The non dystrophic 
myotonias can be dramatic and disabling with potential triggers including: emotional surprise, 
cold, potassium and exercise. The chloride channel (CLC-1) functions in reducing excitability 
and stabilising resting potential whereas the sodium channel renders the membrane 
excitabilty. 
 Chloride channel myotonias include: autosomal dominant myotonia congenita (Thomsen’s 
disease), autosomal recessive myotonia congenita (Becker’s disease), myotonia levior and 
fluctuating myotonia congential. The CLCN1 gene encodes 130kDa chloride channel (CLC-
1) that is expressed exclusively in skeletal muscle. Gain-of-function and loss-of-function 
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mutations in CLCN1 cause two types of myotonia congentia, namely dominantly inherited 
Thomsen type and recessively inherited Becker type respectively. Thomsen type is very rare 
whereas Becker type is more common with 1:50’000 being affected each year (Rüdel 2000).  
 Thomsen type myotonia congentia has a dominant mode of inheritance pattern with 
symptoms begining during infancy or childhood. Clinical presentation includes generalised 
myotonia, muscle hypertrophy in extremities and facial muscles and painless muscle stiffness 
on muscle activation after rest with this stiffness reducing after continued activity termed the 
“warm-up” phenomenon (Mankodi 2008). Emotional surprises, cold and pregnancy can 
worsen myotonia. Muscle strength is normal in Thomsen type myotonia congenita. 
 Becker type myotonia congenita has an autosomal recessive mode of inheritance with clinical 
presentation of generalised myotonia and muscle hypertrophy of lower extremities, shoulders 
and sometimes seen in forearms, hands and anterior neck. Similar to Thomsen type myotonia 
it is exacerbated by cold, prolonged muscle strain, pregnancy and emotional tension. Unlike 
Thomsen type, Beckers type symptoms have an insidious onset and occur later during 
childhood. The symptoms in Becker type are slowly progessive and can stabilise in the third 
decade. Hypertrophy of the lower extremities can become pronounced. Current treatments for 
Thomsen and Beckers type myotonia congenita are activity adjustment and avoidance of 
triggers. 
 
1.3.2 The Chloride Channel 
Chloride channels regulate the anion flow by switching on or off in response to stimuli e.g. 
ligand-binding, changes in voltage and changes in Ca
2+
 intracellular concentration. They are 
present in the plasma membrane and in the membrane of intracellular organelles  and are 
involved in a wide variety of functions including: cell volume regulation, transepithelial 
transport, endocytotic trafficking and stabilisation of the membrane potential.  The voltage-
gated chloride channel ClC-1 found exclusively in skeletal muscle will now be discussed in 
detail based on function and structure. 
  17 
1.3.2.1 Function 
All living cells have charge differences across their membrane and this charge difference 
arises due to differences in ionic composition of intracellular and extracellular fluids and the 
selective permeabiltiy of the plasma membrane. Intracellular and extracellular fluids contain a 
variety of electrically charged ions. The principal positively charged ions (cations) outside the 
cell are sodium ions (Na
+
) with some potassium ions (K
+
). Inside the cell the situation is 
reversed with K
+ 
the principal cation and Na
+
 is in lower concentration. Outside the cell the 
principal negatively charged ion (anion) is chloride (Cl
-
).  Ion channels are pores  that allow 
the movement of ions across the plasma membrane. Internal anions are predominantly large 
organic molecules that cannot pass the plasma membrane they are a constant pool of internal 
negative charge, therefore inside the cell is more negatively charged than outside the cell. 
This difference in charge across the cellular membrane causes an eletrical gradient or voltage 
across the membrane and is called the membrane potential. Muscle cells and neurons have the 
ability to generate active changes in their membrane potential and are called excitable cells. 
When an excitable cell recieves a signal one or more gated ion channels open resulting in Na
+
 
ions moving into the cell bringing a more postive charge. As Na
+ 
builds up inside the cell the 
membrane potential will become less negative reducing the electrical gradient, this process is 
called depolarisation.  Repolarisation of the membrane occurs by rapid Na
+
-channel 
inactivation and opening of K
+
-channels that mediate the outward K
+
 current. (Jurkat-Rott et 
al. 2002). Compared with other excitable cells skeletal muscle has an usually high chloride 
conductance accounting for up to 85% of resting membrane conductance (Bryant et al 1971). 
The high chloride conductance is important due to the large size of muscle fibers that require 
the T-tubule system to propagate an action potential into depth of the cell to initiate 
synchronised contraction of the fiber (Matthews et al. 2010). Chloride conductance plays a 
vital role in maintaining normal muscle excitability and is thought to do this by reducing both 
the accumulation of K
+
 and its depolarising effect in the T-tubule system (Dutka et al. 2008).  
Without the high chloride conductance K
+
 accumulation in the small space of the T-tubule 
system during prolonged muscle activity would increase the normally low intratubular K
+
 
concentration thereby shifting the K
+
 equilbrium potential and depolarising the membrane 
leading to generation of new action potentials. The high Cl
-
 conductance in skeletal muscle 
helps to alleviate this problem. The concentration of Cl
-
 within the extracellular fluid is more 
than an order of magnitude greater than that of K
+
 therefore any effect of Cl
-
 movement out of 
the extracellular fluid and into the cell on the total Cl
-
 concentration in the extracellular fluid 
  18 
and the Cl
-
 equilibrium potential is negligible and the Cl
-
 conductance is able to negate the 
depolarising effect of K
+
 accumulation (Waldegger and Jentsch 2000). Therefore the 
hyperexcitability seen in myotonia is due to a permanent reduction of the resting chloride 
conductance of the muscle fiber membranes. 
  
1.3.2.2 Structure 
Strucutral analysis of chloride channels began by Jentsch and co workers in 1990 with the 
cloning of the Torpedo electric organ Cl
-
 channel ClC-0. ClC-0 was shown to have a “double-
barrelled” structure with two identical pores that gate independently from each other “fast 
gates” also these can be gated simultaneously by another common gate “slow gate”. This 
homodimeric structure where each pore is formed by a single CLC-0 protein was proposed for 
CLC-1 the skeletal muscle Cl
-
 channel by Saviane and co-workers in 1999 and later 
confirmed by X-ray crystallography (Dutzler et al. 2002). The ClC-1 channel is composed of 
18 transmembrane domains with intracellular localisation of the N- and C-termini of the 
protein (Dutzler et al. 2002) and can be seen in figure 1.3. CLC channel proteins share a 
common structural feature: a tandem repeat of cystathionine-b synthase (CBS) domains in the 
carboxy terminus (Schmidt-Rose and Jentsch 1997). The function of the CBS domains are 
unknown although work by Waldegger and Jentsch (2000) whereby deletion of CBS-2 in 
CLC-1 resulted in consistent channel function indicating there is no requirement for this 
domian. Both fast and common gates are activated by depolarisation and deactivated by 
hyperpolarisation (Fahlke and Rüdel, 1995). It is important to note that deactivation by 
hyperpolarisation is not complete and results in a steady-state current therefore the channel 
has an open probability even at very negative voltages (Jentsch 2002). ClC-1 is primarly 
located in  the sarcolemmal membrane of skeletal muscle (Gurnett et al 1995; Mankodi et al. 
2002) which is unusual as physiological investigations revealed that muscle Cl
-
 conductance 
is mainly found in the T-tubule system (Mankodi et al. 2002). It is suggested that either a 
distinctly different Cl
-
 conducting channel or a splice varient of CLC-1 may be present in the 
T-tubule system (Gurnett et al. 1995). ClC-1 is blocked by 9-anthracene-carboxylic acid and 
4-chloro-phenoxy-acetic acid (Jentsch et al. 2005).  
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Figure 1.3 CLC-1 Chloride Channel 
Shown is the skeletal muscle chloride channel CLC-1 as a double-barreled channel with each 
protein forming a channel. Green spheres are chloride ions. Obtained from 
chemistry.umeche.maine.edu/.../1ofs-1.jpg 
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1.3.3 Mutations of CLC-1  
In both dominant myotonia congenita (Thomsen type) and recessive generalised myotonia 
(Becker type), mutations in the gene encoding the major skeletal muscle chloride channel 
CLCN1 result in reduced sarcolemmal Cl
-
 conductance (Adrian and Bryant 1974). This 
abnormal membrane property leads to membrane hyperexcitability, repetitive firing of muscle 
action potentials and clinical myotonia that is characterised by muscle stiffness upon sudden 
forceful movement. Mutations in CLC-1 was first described in the myotonic “arrested 
development of righting response” ADR mouse by Steinmeyer and colleagues in 1991. Then 
in 1993 similar mutations in CLC-1 were identified in human myotonia ( Koch et al. 1993). 
Today 80 mutations have been identified in the CLCN1 gene causing myotonia (Pusch 2002) 
with 40 of these identified in patients with dominant or recessive myotonia (Lehmann-Horn 
and Jurkat-Rott 1999). These mutations include: missense and nonsense mutations, splice-site 
mutations and frame shift mutations (Jentsch 2002). Most mutations lead to recessive 
myotonia congenita where both alleles are mutated and can result in the total loss of CLC-1 
channel function. Dominant myotonia can be explained by mutant subunits which can inhibit 
the function of dimers that are formed with wild type (WT) subunits encoded by the other 
allele. Therefore with dominant Thomsen type myotonia it is expected that heterzygous 
patients will have 25% fully funcional  WT/WT channels. This is shown as myotonia is 
clinically less severe in dominant compared with recessive forms. The first reported mutation 
discovered in Thomsen type myotonia causes the substitution of a glycine residue by glutamic 
acid located between transmembrane segments 4 and 10 in human CLC-1 (George et al. 
1993). Fahlke and colleagues in 1997 looked at another dominant  mutation in CLCN1 which 
was found to affect the pore properties of the CLC-1 channel. There also exists single 
mutations that in some families exhibit a dominant phenotype, whereas in other families the 
recessive phenotype is observed. The fs793X mutation shows dual modes of inheritance (Kuo 
et al. 2006). 
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1.3.4 Myotonia Treatment 
Many myotonia congenita patients manage their disease without medication. If necessary 
myotonic treatments include drugs that reduce the increased excitability of the cell membrane 
by interfering with the sodium channels of muscle membrane. Mexiletine has been tested and 
can be administered orally and is the drug of choice for the treatment of myotonia (Matthews 
et al. 2010).  
 
1.4 Animal Models of Myotonia 
The use of myotonic mouse models has allowed the research of the pathogenesis and the 
molecular  basis of myotonia. 
 In 1984 Watkins and Watts described a mouse mutant with abnormal motor behaviour. The 
spontaneous mutation showed recessive autosomal mode of inheritance and was termed 
“arrested development of righting response” (ADR) as the affected mice had difficulty 
righting themselves when placed surpine. Early analysis showed repetitive action potentials in 
ADR muscle leading to the suggestion that the ADR phenotype was caused by muscle 
membrane abnormality (Mehrke et al. 1986;1988). Steinmeyer and colleagues in 1991 
confirmed that the membrane abnormality was due to an insertional mutation in the CLC-1 
gene.   
 A similar spontaneous mutation was observed by Heller and co-workers in 1982 sharing the 
same physiological features as ADR mutants and was termed “myotonia” (MTO) mutant. 
Both diseased mice were recognised by typical stiffening response to a sudden challenge like 
being turned on their backs. The disease affects first the hind quaters and then forelimbs and 
results in a reduced life span, weight loss and brittleness of bones in both mutant mice. Then 
in 1988 Jockusch and co-workers showed that both independent, spontaneous mutations MTO 
and ADR were allelic. The ADR myotonic mouse (phenotype ADR, genotype adr/adr) is 
caused by an insertional (allele adr) mutation at gene locus Clc1 on chromosome 6 of muscle 
chloride channel CLC-1. In MTO mice myotonia is due to a nonsense mutation (allele mto) at 
the same locus. Myotonic ADR and MTO mice are both genocopies of human congenital 
myotonia. They display a more pronounced  phenotype, making them ideal model systems for 
studying secondary effects of myotonia on skeletal muscle. 
 A new allele mto*5j at the Clc1 locus carries a base insertion in codon 75 which causes a 
frameshift in the reading frame of the gene resulting in a stop codon in position 93. MTO*5j 
mice were discovered at Jackson Laboratory in 2000 and allelism has been shown with MTO 
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mice. MTO*5J mice are midly affected, show less reduced body weights and have a near 
normal life span. The physiological and histochemical properties of MTO*5J muscles are 
intermediate between those of ADR and WT control muscles (Staunton et al. 2011). This 
milder phenotype is clinically closer to human congenital myotonia.  
 All three alleles are null mutations that do not produce CLC-1 protein. The reasons for the 
mild response to a complete CLC-1 deficiency in MTO*5J mutants is not known. 
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1.5 Motorneuron disease 
 Motorneuron diseases represent a class of progressive, neurodegenerative disorders which 
result in the loss of motor neurons. They are characterised by selective and progressive loss of 
lower and/or upper motor neurons.  There are many types of motor neuron disease, such as; 
progressive muscular atrophy, primary lateral sclerosis and amyotrophic lateral sclerosis 
(ALS) (Wijesekera and Leigh, 2009). ALS accounts for the majority of the motor neuron 
diseases and is characterised by the degeneration of motor neurons in the brain and spinal 
cord, resulting in loss of muscle function (Goodall and Morison, 2006). Today, ALS is an 
incurable disease leading to death within three to five years from onset of symptoms. 
Approximately 20% of patients can survive more than five years and only about 10% more 
than ten years (Kuzma-Kozakiewicz and Kwiecinski, 2011).  Patients generally die from 
respiratory failure due to loss of function of repiratory muscles. ALS has an incidence of on 
average 1.89 per 100,000/ year (Wijesekera and Leigh, 2009). Approximately two thirds of 
patients with ALS have spinal form of the disease (limb onset) and present muscle weakness 
and wasting. These symptoms may start either distally or proximally in upper or lower limbs. 
Patients may have noticed fasciculations or cramps preceding onset of weakness or wasting 
for some months. Muscle weakness has gradual onset with other limbs developing weakness 
and wasting eventually patients go on to develop bulbar symptoms. Late stages of the disease 
patients can develop bladder dysfunction, sensory symptoms or cognitive symptoms 
(Wijesekera and Leigh, 2009). In contrast  bulbar onset ALS patients present with dysarthria 
of speech which during early stages of the disease may only occur after the ingestion of small 
amounts of alcohol. Patients develop dysphagia of solids and liquids. Limb symptoms 
develop simultaineously with bulbar and eventually develop sialorrhoea due to difficulty 
swallowing and mild facial weakness (Wijesekera and Leigh, 2009). The rate of disease 
progression varies greatly amoung patients and clinical observations suggest the rate of 
progession of ALS in most patients is not explained by age or site of onset (Beghi et al. 
2007). Therefore the process of motor neuron degeneration in ALS is complex and 
mulifactorial.   
 In 10% of cases ALS is familial and there is a family history of the disease and so are termed 
familial ALS (FALS). In the majority of ALS cases there is no known cause of the disease 
and are termed sporadic ALS (SALS) (Valentine et al. 2005). The clinical and pathological 
characteristics of FALS and SALS are indistinguishable (Baghi et al. 2007).  
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 The molecular pathway causing motor neuron degeneration in ALS is unknown and is 
thought to be due to a multiple of pathogenic cellular mechanisms including: (i) genetic 
factors, (ii) excitotoxicity, (iii) mitochondrial dysfunction, (iv) impaired axonal transport, (v) 
protein aggregation and (vi) oxidative stress. 
 To date mutations in six genes have been discovered to be associated with ALS (Beghi et al. 
2007). Mutations in the Copper-Zinc superoxide dismutase (Cu/Zn SOD) protein encoded by 
the sod1 gene was first described by Rosen and collegues in 1993 as a cause of autosomal 
dominant FALS. Since then 140 mutations in sod1 have been identified they account for 20% 
of all FALS cases and 2% of SALS cases (Rosen et al. 1993). Cu/Zn SOD is an ubiquitously 
expressed anti-oxidant enzyme. Mutations in the gene are thought to cause disease through a 
toxic gain-of-function rather than causing impairment to the antioxidant function of the 
enzyme (Shaw, 2005). Mutations found in ALSIN is the cause of a rare autosomal recessive 
form of ALS characterised by juvenile onset and slowly generalised spasticity (Beghi et al., 
2007). The physiological role of ASLIN and the mechanism by which its mutation causes 
motor neuron degeneration is unclear. It is thought that ASLIN may have a role in axon 
transport (Kunita et al. 2004). A mutation that has been found to affect axonal transport is that 
in dynactin. Dynactin is the largest polypeptide of the dynactin complex and functions in 
retrograde axonal transport of vesicles and organelles along microtubules (Holzbaur and 
Tokito 1996). Other mutations have been found in senataxin and vesicle associated protein B 
(VAPB). Recently a mutation in TARDBP gene have been linked to both FALS and SALS 
(Wijesekera and Leigh 2009).  
  The term excitotoxicity is used to describe neuronal injury induced by excessive glutamate 
induced by stimulation of postsynaptic glutamate receptors (Wijesekera and Leigh 2009). 
Over stimulation of glutamate receptors is thought to result in massive calcium influx into 
neurons leading to increased nitric oxide formation and thereby neuronal death. Glutamate 
levels in the cerebral spinal fluid (CSF) have been shown to be elevated in some patients with 
ALS (Shaw et al. 1995). This elevation has been attributed to loss of astroglial glutamate 
transporter (EAAT2) protein found in affected regions of ALS patients (Rothstein and Kunel 
1995). The loss of EAAT2 could be an indirect consequence of neuronal death as expression 
of glial glutamate transporters is regulated by neuronal activity (Beghi et al. 2007). It is 
unclear if the alteration in glutamate metabolism in ALS patients are a consequence or cause 
of disease.  
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 The first suggestion of a role for mitochondrial dysfunction in ALS came from the obseration 
of abnormal mitochondrial morphology in tissues of ALS patients. Mitochondria from 
transgenic sod1 mice show elevated calcium levels and decreased activity of respiratory chain 
complexes I and IV implicating defective energy metabolism (Barber and Shaw 2010).  
 Neurofilaments are major components of the motor neuron’s cytoskeleton and function in the 
regulation of axonal transport. Accumulation of neurofilaments in motor neurons and their 
axons is a hallmark of ALS (Kuzma-Kozakiewicz and Kwiecinski 2011) but it is unknown if 
this accumulation is a primary or secondary effect in neurodegeneration.  
 Intraneuronal aggregates such as bunina bodies, ubiquitinated skein-like inclusions and 
neurofilament rich hyaline conglomerate inclusions have been found in motor neurons and are 
hallmarks of ALS. The formation of these protein aggregates may be due to impaired 
degradation of misfolded mutant proteins e.g Cu/Zn SOD or dysfunction in the ubiquitin-
proteasome pathway (UPP).  
 Oxidative stress has long been linked to neurodegeneration and it is known that accumulation 
of reative oxygen species (ROS) cause cell death. This thought is backed by the fact 
mutations in sod1 gene cause FALS. 
 
1.5.1 Treatment of ALS 
Numerous compounds have been tested as potential disease modifying therapies for ALS yet 
only the drug riluzole has been licensed for this purpose (Miller et al. 2007). Riluzole exerts 
its protective effect in ALS patients by acting as an antiexcitotoxic agent (Lacomblez et al. 
1996). Riluzole acts by blocking different processes including the release of glutamate from 
presynaptic neurons and therefore can inhibit the glutamate-mediated overstimulation of 
postsynaptic glutamate receptors (Pratt et al. 1992). Clinical trials using riluzole prolonged 
ALS survival in patients by 3-6 months (Lacomblez et al. 1996). The effect of riluzole 
enforces the idea of glutamate-induced excitotoxicity in ALS.  
 Other drugs that have recieved attention are the tetracycline derivative minocycline. 
Minocycline is a multifunctional drug that affects different molecular pathways involved in 
ALS. One function of minocycline is that it inhibits cytochrome C release from the 
mitochondria and has been shown to delay the disease onset and also extend survival in sod1 
transgenic mice (Zhu et al. 2002).  
 Olesoxime is a steroidal oxime which binds to the mitochondrial permeability pore and 
shows potential efficacy in preclinical models of ALS and spinal muscular atrophy (Bordet et 
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al. 2007). Also dexpramipexole and pramipexole are both drugs that have shown 
neuroprotective properties by reducing ROS production. 
 The wide array of drugs that have been tested for the treatment of ALS only confirm the idea 
that ALS is a multifactorial disease with a multitude of cellular mechanisms that lead to motor 
neuron death. 
 
1.5.2 The Wobbler Mouse 
The Wobbler mouse suffers an autosomal recessive mutation producing severe motorneuron 
degeneration and astrogliosis in the spinal cord. It is considered a suitable animal model for 
motor neuron disease such as ALS. The mutation arose as a spontaneous mutation in the 
Institute of Animal Genetics, University of Edinburgh, Edinburgh, Scotland. The name 
“Wobbler” is due to the fine tremor of the head mice experience by week four. Homozygous 
(wr/wr) mice show no clinical abnormality during the first three weeks, by the fourth week 
they are smaller than their littermates and remain so, they also experience a high stepping, 
unsteady gait along with tremor of the head. From week four to week five weakness of the 
muscles become apparent and is most obvious in forelimbs. By week twelve there is 
progressive weakness of the head, neck and forlimbs with hindlimbs less affected. In 
advanced stages of the disease mice have difficulty using forelimbs for climbing and walking. 
By the third or fourth month the disease seems to slow down in progression in some whereas 
in others the disease is fatal by the third or fourth month. Motor neuron degeneration in the 
Wobbler mouse is confined to the cervical spinal cord region, with the lumbar spinal cord 
remaining unaffected (Bastone et al. 2009). The Wobbler mouse also shows defective 
spermiogenesis in males (Pérez-Victoria et al. 2010).  
 A missense mutation whereby  leucine 967 is changed to glutamine near the C-terminus of 
the vescile sorting protein 54 (Vsp54) is responsible for the wobbler phenotype (Schmitt-John 
et al. 2005). VSP 54 is a subunit of the Golgi-associated retrograde protein (GARP) complex 
and is responsible for the transport of vesicles to the trans-Golgi network (Schmitt-John et al. 
2005). The GARP complex is a herterotetrameric complex composed of four subunits; Vsp51, 
Vsp52, Vsp53 and Vsp54. Pérez-Victoria and co-workers (2010) looked at the structural 
consequence of the wr mutation and found that leucine967 is critical for domain stability and 
folding and therefore the wobbler phenotype results from the destabilisation of Vsp54 and 
thus reduced levels of Vsp54 and addtionally the GARP complex. Meisler and colleagues 
(2008) found no direct link between Vsp54 mutation and human ALS. However, the Wobbler 
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mouse is considered a suitable model for neurodegenerative disease due to the similarities 
between clinical features of motor neuron degeneration in wobbler mice and in humans, thus 
suggesting the possibility of common pathways in both. 
Studies on the wobbler mouse have focused on the spinal cord (Bastone et al. 2009) and 
motor neurons (Meyer et al. 2010) in order to gain a greater understanding of the pathogenesis 
of motor dengeneration in the mouse. In contrast, very little is known of the secondary effects 
of motor neuron degeneration on skeletal muscle. Previous studies have looked at the 
proportions of MHC in affected muscles (Agbulut et al. 2004) whereby a shift to the fast 
MHCIIB was found in wobbler tibialis anterior muscles. Analysis at the mRNA level has also 
been looked at in the skeletal muscle of the wobbler mouse (Sedehizade et al. 1997). 
Sedehizade and colleagues looked at the mRNA levels of myogenic factors myogenin and 
MyoD that function in gene transcription and the Ca
2+
-binding protein parvalbumin. 
Myogenin mRNA was elevated in wobbler skeletal tissue whereas parvalbumin mRNA was 
decreased (Sedehizade et al. 1997). In order to understand fully understand the secondary 
effects of the loss of motor innervation has on the skeletal muscle proteome, it is neccessay to 
gain a wider picture of the changes in the protein complement of the wobbler skeletal tissue. 
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1.6 Proteomics 
The complement of proteins expressed by a cell is referred to as its proteome. The skeletal 
muscle proteome is highly dynamic, and differs from fiber to fiber. Proteomics is the study of 
the proteins expressed by a cell. There are two main fields in proteomics; expression 
proteomics and functional proteomics. Expression proteomics involves the denaturation  of 
proteins, and using subsequent analysis to determine quantitative changes in the abundance  
of proteins under different condition. In contrast, functional proteomics involves maintaining 
the proteins native structure and gaining functional information on that protein. It is important 
to note that translation of the nucleotide sequence has been shown not to match fully with the 
proteins produced in the cell (Anderson and Seilhamer 1997). This is because the proteome is 
subjected to environmental influences that can act to apply post translational modifications 
(PTM) to adapt to a change in situation. For example, altered neuromuscular activity leads to 
increased cytosolic Ca
2+
 resulting in decreased expression of transcription factors resulting in 
a changed transcription pattern in the muscle cell. This has been shown at the mRNA level 
whereby denervation due to motor neuron disease results in a decrease of the transcription 
factor myogenin mRNA in skeletal tissue from the wobbler mouse (Sedehizade et al. 1997). 
A decrease of transcription factors may play a role in the fiber type transformation seen in 
wobbler skeletal muscle whereby there is a shift to faster MHCIIB expression in wobbler 
muscle tissue (Agbulut et al. 2004).  
 Expression proteomics begins with the solubilisation of the sample of proteins. Denaturing 
buffers are used for this process and contain a combination of chemicals to solubilise the 
maximum amount and variety of proteins. They are usually composed of 7-9M Urea to 
disrupt hydrogen bonds, along with detergents such as CHAPs and reducing agent such as 
DTT. There is no standard solubilisation buffer as they must be tailored to the sample to 
achieve optimum solubilisation. 
 
1.6.1 Two Dimensional Gel Electrophoresis 
Many proteomic techniques exist to separate and analyse proteins. One of the most powerful 
techniques for separating entire proteomes is the use of two-dimensional gel electrophoresis 
(2-D GE). This technique was first developed by O’Farrell in 1975 and involves the 
separation of proteins in two dimensions. In the first dimension proteins are separated on thin 
strips of polyacrylamide gel containing an immobilised pH gradient (IPG). These IPG strips 
are purchased as precast dehydrated gels supported by backing plastic. In the first dimension 
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proteins must enter the gel before they are separated. This can be done by a number of 
methods, firstly the strips are rehydrated using rehydration buffer. Protein sample can be 
added to the rehydration buffer and can enter the gel passively, or after rehydration during 
isoelectric focusing (IEF). As an electric current is applied to the IPG strip during IEF 
proteins move through the gel until they reach a pH where they no longer have a net charge. 
In this dimension a number of different pH gradients can be used. Narrow pH ranges can be 
used to give better separation of proteins and allow an increased nmber of proteins to be 
visualised. In the second dimension the IPG strip is placed horizontally along the top of a 
large polyacrylamide gel. An electric current is passed through the gel and forces the proteins 
through pores in the gel, smaller proteins will move faster through the gel than larger proteins. 
Therefore in the second dimension proteins are separated based on their molecular weight. 
 There are a number of limitations to this technique for example IPG strips have a limited 
capacity for the amount of protein they can hold and proteins above a certain size cannot enter 
the gel matrix of the IPG strip. Proteins of a very low molecular weight may run too quickly 
through a 2-D gel, and so become lost. Also insoluble proteins such as those found in the 
sarcolemma or membrane proteins are notoriously hydrophobic and will not go into solution 
easily and do not like the aqueous environment of the second dimension. 
 
1.6.2 Visualising Proteins 
After 2-DE, the separated proteins have to be visualised by staining techniques. The 
concentration of individual proteins in a cell differ between 6-7 orders of magnitude ranging 
from millions of copies for highly abundant proteins such as contractile proteins in muscle 
cells  to a few copies for low abundant proteins. This is a major challenge for almost all 
protein detection methods available today. Important properites of protein visualisation 
methods include; (i) high sensitivity, (ii) high linear dynamic range, (iii) reproducabilty and 
(iv) compatability with protein identification methods. Today current stains that are widely 
used in proteomic studies are staining with anionic dye e.g. Coomassie blue, silver staining 
and fluorescence staining. 
 Coomassie brilliant blue (CBB) is used for the widespread detection of proteins due to its 
low price, ease of use and compatibility with protein identification methods. The limitations 
with CBB is its insufficient sensitivity as it cannot detect low abundance proteins. 
 Silver staining is alot more sensitive than CBB staining and only requires 100 mg of protein 
per gel for detection. Unlike CBB, silver staining is not reproducable due to its subjective 
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end-point of the staining procedure and so makes silver staining less suitable for quantitative 
analysis. 
 Better and more confident results in terms of sensitivity and linear dynamic range of 
detection are obtained by protein detection relying on fluorescent compounds. Fluorescent 
detection of proteins can be done in two ways; firstly by the covalent derivatisation of 
proteins with fluorophores prior to separation techniques or secondly by post-electrophoretic 
protein staining. Pre-electrophoretic protein staining can be carried out using fluorescent 
labels e.g. cyanine-based dyes, that react with the lysyl residues of proteins. Proteins can also 
be stained with a fluorescent dye molecule after electrophoretic separation. The cost efficient 
ruthenium II tris (bathophenanthroline disulfonate) developed by Rabilloud and co-workers in 
2001 is now widely used due to its ease of use and compatability with protein detection 
methods. 
 
1.6.3 Protein Identification 
The Identification of proteins after 2-D gel electrophoresis is carried out using mass 
spectrometry. Sample preparation for mass spectrometry begins with desalting and destaining 
of samples to remove contaminants. The samples are then enzymatically digested e.g using 
trypsin which cleaves proteins at lysine and arginine amino acid residues. When applied to the 
mass spectrometer samples go through several processes including; ionisation, analysis and 
detection.  
 
1.6.3.1 Mass Spectrometry 
By definition a mass spectrometer (MS) consists of an ion source, a mass analyser that 
measures the mass-to-charge ratio (m/z) of the ionised analytes and a detector that regisiters 
the number of ions at each m/z value (Abersold and Mann 2003). Throughout this project an 
ion trap LC/MS has been used for protein identification. 
 The ion source used was electrospray ionisation (ESI) whereby peptides are dissolved in a 
polar solution then pumped through a narrow capillary tube. The sample travels through the 
tube and on exiting the tip of the tube it has a high voltage applied to it. This causes the 
sample to form an aerosol which is directed towards the mass spectrometer by a gas usually 
nitrogen. The warm nitrogen gas causes the solvent to evaporate allowing free ions to enter 
the mass spectrometer (Yamashita and Fenn 1983).  
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 Ions then enter the ion trap where they are captured or “trapped” for a certain amount of time 
and then subjected to MS/MS analysis. Ion traps are often used as they are robust and 
relatively inexpensive.  
 Fragment ions are produced by bombardment with an inert gas. The ions are first analysed in 
normal mode, then parent ions are fragmented again by collision induced dissociation 
resulting in MS/MS spectra. The spectra of peptide ions produce several masses and are then 
searched in protein data bases such as MASCOT to identify the protein of interest.  
 
1.7 Membrane proteomics 
Membrane proteins are proteins that integrate into the phospholipid bilayer of membranes and 
play important role in cell-to-cell interactions, signal transduction and molecular transport 
(Groen and Lilley 2010). Two main challenges are imposed by proteomic analysis of 
membrane proteins; firstly they are extremely hydrophobic and secondly they are present in 
low abundance and therefore can be underrepresented in proteomic analysis. A multitude of 
methods have been developed in order to over come these challenges from solubilisation 
methods such as the use of Triton X-114 whereby  proteins are separated into aqueous and 
detergent phases (Staunton et al. 2010).  One method that has been sucessfull in overcoming 
problems incountered with 2-DE proteomics is the digestion of proteins on nitrocellulose 
membranes. 
 
1.7.1 Digestion on nitrocellulose membrane 
The digestion of proteins with trypsin from nitrocellulose membranes was first described by 
Abersold in 1987. This method overcame problems incountered with 2-DE proteomics as it is 
easier for large membrane proteins to enter large gradient gels. Proteins are transferred to the 
membrane via electrostatic interactions and hydrophobic binding. The membrane bound 
proteins can be directly digested thus reducing the loss of peptides that can occur during wash 
steps.  
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1.8 Aims of the project 
The purpose of this study was to carry out proteomic profiling of skeletal muscle from mouse 
mutants affected by myotonia and motor neuron disease. Myotonia congenita is a skeletal 
muscle disorder and is classified as a muscle hyperexcitability or a delay in muscle relaxation. 
In order to fully understand the effects of hyperexcitability on the skeletal muscle we have 
carried out proteomic profiling of skeletal muscle from three mouse mutants: ADR, MTO and 
MTO*5J. As the MTO*5J mutant shows a less severe phenotype we can assess the changes 
comparatively between the MTO*5J and more severly affected ADR and MTO mice. In 
contrast to myotonia motor neuron disease results in the loss of motor neurons and so a loss of 
muscle innervation. In this study we have carried out proteomic profiling of skeletal muscle 
from the wobbler mouse mutant an animal model for the motor neuron disease ALS. By 
looking at the secondary effects of muscle denervation due to motor neuron loss we can 
potentially establish biomarkers for the disease. By using 2-D gel electrophoresis we can 
establish the changes in the global protein expression pattern in skeletal muscle effected by 
these muscle diseases. 
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2. Materials and Methods 
 
2.1 Materials 
2.1.1 General chemicals and reagents 
General reagents and chemicals were purchased from Sigma Chemical Company (Dorset, 
UK) and were of reagent/electrophoresis grade, unless otherwise stated. Distilled H2O was 
purified using a Millipore Milli-Q apparatus to obtain milli-Q water. The bradford reagent for 
protein quantification was purchased from Biorad (Bio-Rad Labs., Hemel0Hempstead, Herts., 
UK). Protease inhibitors were from Roche Diagnostics (Manheim, Germany). 
 
2.1.2 1-D and 2-D electrophoresis 
Ultrapure Protogel acrylamide stock and 4X Protogel Resolving Buffer stock solutions were 
obtained from National Diagnostics (Atlanta, GA, USA). Isoelectric focusing pH Gradient 
(IPG) drystrips for 2-D electrophoresis, ampholytes and cover fluid were purchased from 
Amersham Bioscience/GE Healthcare (Little Chalfont, Bucks, UK). Protein molecular weight 
ladders and laemmli buffer were purchased from Biorad Laboratories (Hemel-Hempstead, 
Herts., UK).   
 
2.1.3 Staining 
Coomassie Blue R-350 tablets were purchased from  Amersham Biosciences/GE Healthcare 
(Little Chalfont, Bucks, U.K). Bathophenanthrolinedisulfonic acid and disodium salt hydrate 
for RuBPs dye were purchased from Reagecon Diagnostic Limited (Shannon, Ireland). 
Sodium Ascorbate for RuBPs was purchased from Sigma Chemical Company (Dorset, U.K). 
DIGE dyes were purchased from GE Healthcare (Little Chalfont, Bucks., UK).  
 
2.1.4 Mass Spectrometry 
All solvents used for Mass Spectrometry analysis were of Mass Spectrometry grade and 
purchased from Sigma Chemical Company (Dorset, UK). Acetonitrile was obtained from 
Amersham Biosciences/GE Healthcare (Little Chalfont, Bucks., UK) Sequencing grade 
modified trypsin was purchased from Promega (Madison, WI, USA). LC-MS Chromaslv 
water and formic acid were from Fluka (Dorset, UK). Model 6340 Ion Trap LC/MS, LC/MS 
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vials, LC/MS vial caps and ProtlD-Chip-150 II 300A C18 150nm col were obtained from 
Agilent Technologies Ireland Ltd. (Santa Clara, CA, USA). 
 
2.1.5 Western Blotting 
Nitrocelulose membrane was obtained from Millipore (Bedford, MA, USA). 
Chemiluminscence substrate was purchased from Roche Diagnostics (Manheim, Germany). 
X-ray film was purchased from Fuji Photo Film Co. Ltd. (Tokyo, Japan). GBX 
Developer/Replenisher, GBX Fixer/Replenisher and Ponceau S-Red Staining Solution were 
obtained from Sigma Chemical Company (Dorset, UK). Memcode reversible stain was 
purchased from Thermo Scientific ( MA, USA). All secondary antibodies used were obtaned 
from Chemicon International (Temecula, CA., USA). All commerically available antibodies 
used in this research were purchased from the companies detailed see Table 2.1. For 
antibodies used and dilutions see Table 2.2. 
 
 
 
 
Table 2.1 Antibody Suppliers 
 
Company Address 
Abcam Abcam Plc (cambridge, UK) 
ABR Affinity Bioreagents (Golden, CO., USA) 
Santa Cruz Biotechnology Santa Cruz, CA, USA. 
Sigma Dorset, UK 
Upstate Biotechnology Lake Placid, NY. 
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Table 2.2 Antibodies 
List of antibodies used for this project including the dilutions used for each primary and 
secondary antibody, host species (species) and ordering information. 
Antibody 1
o
 Ab 
dilution 
Species 2
o
 Ab 
dilution 
1
o
 order 
no. 
Company 
Adenylate Kinase 1:1000 Ms 1:1000 Ab54824 Abcam 
Aldolase 1:1000 Rb 1:1000 Ab6910 Abcam 
Alpha 
dystroglycan 
1:1000 Ms 1:1000 05-298 Upstate 
Calsequestrin 1:1000 Rb 1:1000 MA3-913 ABR 
Creatine Kinase 1:500 Rb 1:1000 Ab38178 Abcam 
Cu/Zn SOD 1:500 Rb 1:1000 Ab13498 Abcam 
Desmin 1:1000 Rb 1:1000 Ab8592 Abcam 
GAPDH 1:1000 Gt 1:1000 Ab34492 Abcam 
MHC-fast 1:1000 Ms 1:1000 Ab51263 Abcam 
MHC-slow 1:1000 Ms 1:1000 Ab11083 Abcam 
MLC-2 1:1000 Rb 1:1000 Ab48003 Abcam 
MLC-phospho20 1:1000 Rb 1:1000 Ab2480 Abcam 
MYBP 1:1000 Ms 1:1000 Ab55559 Abcam 
Myoglobin 1:500 Rb 1:1000 M-8648 Sigma 
Parvalbumin 1:1000 Rb 1:1000 Ab11427 Abcam 
Ryanodine 
receptor 
1:500 Ms 1:1000 MA3-925 ABR 
Sarcalumenin 1:1000 Ms 1:1000 Sc-58845 Santa Cruz 
SERCA1 1:1000 Ms 1:1000 MA3-912 ABR 
SERCA2 1:1000 Ms 1:1000 MA3-919 ABR 
Triosephosphate 
isomerase 
1:1000 Gt 1:1000 Ab28760 Abcam 
Tropomyosin 1:1000 Ms 1:1000 Ab7785 Abcam 
Troponin T 1:1000 Gt 1:1000 Ab30807 Abcam 
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2.2 Methods 
 
2.2.1 Animals and Dissections 
Tissue from C57 BL6 control mice and age-matched myotonic and wobbler mice were 
obtained from the Animal House of the University of Bielefeld. Animals were kept under 
standard conditions and all procedures were performed in accordance with German guidelines 
on the use of animals for scientific experiments. The gastrocnemius muscle from ADR, MTO, 
MTO*5J, and control mice were dissected, snap frozen in liquid nitrogen and stored at -70
o
C. 
Similarly the gastrocnemius, tibialis anterior and vastus lateralis were dissected from wobbler 
and control mice, snap frozen in liquid nitrogen and stored at -70
o
C. 
 
2.2.2 Extraction of Total Muscle Protein Complement 
Muscle tissue samples were kept frozen in liquid nitrogen while being ground into a fine 
powder using a motar and pestle. Equal quantities of 100mg wet weight of muscle were used 
for both control and diseased samples. The powder was placed into 1 ml of lysis buffer (7M 
Urea, 2M Thiourea, 2M (3-[3-Cholamidopropyl)-Dimethylammonio]-1-Propane sulfonate) 
(CHAPS), 100mM dithiothretiol (DTT), 5% (v/v) ampholytes and 5tabs protease inhibitor 
cocktail containing 1mM leupeptin, 1.4 mM pepstatin, 0.15mM soybean trypsin inhibitor, 0.2 
mM prefabloc, 0.3 mM E-64, and 1mM EDTA. Samples were homogenised for 10 s each 
with a plytron hand held homogeniser (Polytron PT, 1200, Kinematica AG, Switzerland). 
DNA was removed by the addtion of 10ml of DNAase-1 per 1ml lysis buffer. Samples were 
then incubated at room temperature for 2.3 h on a rotatory shaker and vortexing every 20 min 
for 10 s. The suspension was spun at 14,000 x g for 20 min at 4
0
 C using Eppendorf 5417 R 
centrifuge (Eppendorf, Hamburg, Germany). The resulting pellet and top layer was discarded 
with the middle layer of supernant being retained and stored at -70
o
C. 
 
2.2.3 Acetone Precipitation 
Samples were first precipitated by adding 100% of ice cold acetone at a dilution of 1:4 with 
protein sample and vortexing briefly. The mixture was incubated for 1 h at -70
o
C. The sample 
was then centrifuged for 15 min at 5,000 x g in Eppendorf 5417 R centrifuge (Ependorf, 
Hamburg, Germany) and the supernatant was discarded. The pellet was then resuspended in 
four times the equal volume of the original sample of 80% ice cold acetone and left in -70
o
C 
for 1 h, this proceedure was repeated three times before being resuspended in an appropriate 
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volume of lysis buffer. Resuspension of the sample was aided by vortexing or sonication with 
a sonoplus HD 2200, Bandelin (Berlin, Germany). 
  
2.2.4 Protein Quantification 
Proteins were quantified using a Bradford assay. A standard curve was prepared by dilutng a 
stock solution of 5mg/ml BSA with milli-Q water in the range of 0-100mg BSA. Standards 
were diluted with different dilutions of milli-Q water and 0.1 M HCL. 5 ml of sample/5ml of 
lysis buffer were also diluted with 80ml of milli-Q water and 0.1 M HCL. To both samples 
and standards 3.5 ml of working bradford reagent (1 part bradford reagent dye: 3 parts 
distilled water) was added, mixed and incubated at room temperature for 10 min. Absorbance 
was read for the standards and samples at 595 nm and protein concentration was obtained by 
comparing unknown samples to the standard curve (Bradford, 1976). 
 
2.2.5 1-D Gel Electrophoresis 
One dimensional SDS polyacrylamide gel electrophoresis was performed according to 
Laemmli (1970), using a Bio-Rad Mini-Protean III gel system (Bio-Rad Labs., Hemel-
Hempstead, Herts., UK). Ten percent resolving gel was made of 10% (w/v) acrylamide from 
protogel acrylamide stock, 4X Protogel resolving buffer, 0.438 M SDS, 0.69 M APS and 
0.1% (v/v) N, N, N’, N’-tetramethylethylenendiamine (TEMED). The stacking gel was made 
of 5% (w/v) acrylamide, 0.5M Tris-PO4 pH6.7, 0.438 M SDS, 0.69 M APS and 0.1% (v/v) 
TEMED. Resolving gel was poured first and allowed to polymerise and stacking gel was 
layered over the resolving gel. Samples were boiled for 10 min in Laemmli buffer with 350 
mM DTT in a 1:1 dilution before loading onto the gel. 5- 10mg of protein was loaded per 
well. Electrophoresis was carried out using running buffer (0.0125 M Tris, 0.69 M Glycine, 
0.1% (w/v) SDS) and at 50 volts until the tracking dye ran off the end of the gel. 
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2.2.6 2-D Gel Electrophoresis 
IPG strips for isoelectric focusing were firstly rehydrated for 12 h in rehydration buffer (7 M 
urea, 2 M thiourea, 4% CHAPS, 2% (v/v)ampholytes, 2% (v/v) DTT and 0.05% (w/v) 
bromophenol blue as tracking dye) and sample in a re-swelling tray from Amersham 
Biosciences/GE Healthcare (Little Chalfont, Bucks., UK). Different volumes were used 
according to the IPG strip length and amount of sample required depending on staining 
technique. For 24 cm IPG strips a total volume (rehydration buffer and sample) of 450ml was 
used, for 18 cm IPG strips a total volume of 350ml was used. After re-swelling, the IPG strips 
were loaded gel side up in an Amersham Ettan IPGphor manifold and covered with 108 ml of 
coverfluid. The following running conditions were used for pH3.0-10.0 and pH 4.0-7.0 24 cm 
strips, and 18 cm pH6.0-11.0 strips: 120min at 100V (step and hold), 90min at 500V(step and 
hold), 60min at 1000V(step and hold), 60min at 2000V(step and hold), 60min at 4000V(step 
and hold), 120min at 6000V(step and hold), 240min at 8000V(step and hold), 180min at 
500V(step and hold) and 240min at 8000V(step and Hold) for a total of 70’000 Vh. 
Following first-dimension separation, gel strips were equilibrated for 30min. For the first 
20min gel strips were washed in equilibration buffer containing 100mM dithiothreitol 
followed by 10min of equilibration buffer containing 0.25M ideoacetamide. Using the Ettan 
Dalt-Tweleve system from GE Healthcare (Little Chalfont, Bucks., UK), the gel  
electrophoretic separation of muscle proteins in the second dimension was performed with 
standard 12.5%(w/v) slab gels that were made in the lab and used following 12h of 
polymerization. Following  washing in SDS running buffer, isoelectric focusing strips were 
placed on the top of the second dimension gel and held in place with a 1%(w/v) agarose 
sealing gel. Twelve slab gels were run in parallel at 0.5W/gel for 60 min and then 15W/gel 
until the blue dye front had disappeared from the bottom of the gel. 
 
2.2.7 1-D gel electrophoresis for susequent digestion 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis was carried out with 3-12% 
gradient (1.5 mm thickness; 16 cm length) at a constant setting of 200 V until the blue dye 
front had disappeared from the bottom of the gel. Electrophoretic transfer to nitrocellulose 
sheets was performed for 90 min at 100 V. The reversible staining of membrane sheets was 
carried out with Ponceau Red or MemCode dye to visualise and evaluate the successful 
electrophoretic transfer of SR proteins.  
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2.2.8 DIGE Labelling 
Cy3 and Cy5 dyes were reconstituted as a stock solution of 1mM in fresh DMF 
(Dimethylformamide) and then diluted to a 0.2mM solution prior to use. Protein samples were 
suspended in 1ml of DIGE lysis buffer (9.5M urea, 4% w/v CHAPS, 30mM Tris-Cl, pH8.5). 
Labelling was performed with 200pmols of Cy3 fluor dye per 50mg protein. A 50mg protein 
sample was labelled for each of the protein samples being studied, normal extracts and 
wobbler extracts were each labelled with Cy3 dye and the pooled internal standard with Cy5 
dye. The labelling reaction was carried out for 30min on ice and in the dark, and then 
quenched by incubation with 10mM lysine for 10min on ice. The labelled protein extracts 
were pooled and immediately used for electrophoresis. An equal volume of 2X buffer (9.5M 
urea, 4%CHAPS, 2%IPG buffer pH3.0-10.0 and 100mM DTT) was added and this 
suspension was left on ice for 10min prior to electrophoresis separation. 
 
2.2.9 DIGE Image Acquisition and Analysis 
Labelled proteins were visualised using the Typhoon Trio vaiable mode imager from 
Amersham Biosciences/GE Healthcare (Little Chalfont, Bucks., UK) at a scanning 
wavelength of l=550nm for Cy3 and l=650nm for Cy5 labelled proteins. The PMT values for 
gels analysed were between 500V and 700V and the maximum pixel volume was between 
85,000 and 95,000. Scanning was performed at 50mm resolution for DIGE gels and 100mm 
resolution for RUBPs stained gels. The gel images were then analysed using Progenesis Same 
Spots software version 3.2.3 from NonLinear Dynamics (Newcastle Upon Tyne, UK). All 
gels in an experiment were alligned to a reference gel. Spots were then detected and filtered. 
After filtering, images were then separated in to groups (control verus disease) and spots were 
then analysed to detect changes in abundance. A list was formed of spots with changed 
abundance. An power score was given to each spot above 0.8 and any below 0.8 were 
excluded from consideration. Similarly, spots with a P value less than 0.05 were taken and 
those greater than 0.05 were excluded from the experiment. An anova score was determined 
using the one way anova test. Any spot with Anova score above 0.5 were excluded from 
consideration. Any spots that met all criteria were susequently identified by Liquid 
Chromatography-Mass Spectrometry. 
   
  40 
2.2.10 Protein Staining 
2.2.10.1 Collodial Coomassie Staining 
Colloidal Coomassie staining was carried out according to Neuhoff and co-workers (1988). 
After electrophoresis gels were washed twice with dH2O and placed into Colloidal Coomassie 
staining solution (1 Part Stock Solution A(5% (w/v) Coomassie Brilliant Blue G250), 40 parts 
Stock Solution B(10% (w/v) ammonium sulfate, 2% (v/v) phosphoric acid), 10 parts 
methanol) and incubated overnight. The gels were washed with neutralisation buffer (0.1M 
Tris-PO4 adjusted to pH6.5) for 1-3 min. The background was reduced by washing with 25% 
methanol for 1 min and the dye was fixed overnight in fixation solution (20% (w/v) 
ammonium sulphate). The procedure is repeated 3-4 times until sufficient protein pattern is 
visualised. 
 
2.2.10.2 Silver Staining 
Silver staining was carried out according to Chevallet and collegues (2006). After 
electrophoresis gels were fixed in 30% ethanol, 10% acetic acid for a minimum of 30min. The 
gels were then rinsed twice using 20% ethanol for 10 min and then twice with milli-Q for 10 
min. The proteins were then sensitised by placing the gel in sensitising solution (0.8 mM 
sodium thiosulfate) for 1 min. The gels were then rinsed twice with milli-Q for 10 min. The 
proteins were then stained with 2 mM silver nitrate for a minimum of 20 min to 2 h. The gels 
were then rinsed with milli-Q for 10 s and then developed with 3% sodium carbonate, 250 ml 
formalin, 125 ml 10% sodium thiosulfate made up to 1L with milli-Q. In order to stop 
development gels were placed into stopping solution (40g Tris, 20 ml acetic acid /1L milli-Q). 
Gels were scanned using a Umax Image Scanner from Amersham Biosciences/GE Healthcare 
(Little Chalfont, Bucks., UK). Gels were then stored in a 5% acetic acid solution. 
 
2.2.10.3 RuBPs Stain Preparation 
Ruthenium II Bathophenathroline Disulfonate Chelate 20 mM stock solution was prepared 
according to Rabilloud and co workers (2001). Potassium pentachloro aquo ruthenate (0.2g) 
was dissolved in 20 ml of boiling dH2O and kept under reflux having a deep red-brown 
colour. Bathophenanthroline disulfonate (3 M) was then added and kept under reflux for 20 
min giving the solution a greenish-brown colour. Five milliliters of a 500mM sodium 
ascorbate solution was then added and kept under reflux for another 20 min until the solution 
turned a deep orange-brown colour. The solution was allowed to cool and was then adjusted 
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to pH 7.0 with sodium hydroxide. The final volume was adjusted to 26 ml with dH2O.  The 
stain was stored at 4
o
C and kept for several months. 
 
2.2.10.4 RuBPs staining 
Following electrophoresis gels were placed in 30% ethanol, 10% acetic acid overnight in 
order to fix proteins in the gel. The gels were then washed three times in 20% ethanol for 30 
min. The gels were then stained for 6 h in 20% (v/v) ethanol  containing 200 nM of ruthenium 
chelate. Following staining gels were destained for 15 h in 40% ethanol, 10% acetic acid. 
Gels were then re-equilibrated twice for 10 min in dH2O. Gels were scanned using Typhoon 
Trio vaiable mode image from Amersham Biosciences/GE Healthcare (Little Chalfont, 
Bucks., UK) at a scanning wavelength of l=650nm. The PMT values for gels analysed were 
between 500V and 700V and the maximum pixel volume was between 85,000 and 95,000. 
Scanning was performed at 100mm resolution for RuBPs stained gels. 
 
2.2.10.5 Hot Coomassie Staining 
The staining solution (0.025% (w/v) PhastGel Coomassie Blue R-350 blue tablet and 10% 
(w/v) acetic acid) was heated to 90
o
C and poured over gel to be stained. The gel was placed 
on shaker for 1 h. To destain gels were placed in 10% (w/v) acetic acid with knot of tissue to 
soak up excess coomassie dye. Gels were scanned using a Umax Image Scanner from 
Amersham Biosciences/GE Healthcare (Little Chalfont, Bucks., UK). Gels were then stored 
in a 1% acetic acid solution. 
 
2.2.11 Liquid Chromatography-Mass Spectrometry 
The mass spectrometric analysis of peptides was carried out on a 6340 Model Ion Trap 
LC/MS apparatus from Agilent Technologies (Santa Clara, CA). Excision, washing, 
destaining and treatment with trypsin was performed by an optimised method (Doran et al. 
2004). Trypsin-generated peptides were obtained by removing supernatants from digested gel 
plugs. Further recovery was achieved by adding 30%acetonitrile/ 0.2%trifluoroacetic acid to 
the gel plugs for 10min at 37
o
c with gentle agitation. Resulting supernatants were pooled with 
the initially recovered cohort of peptides following trypsin digestion. Further peptide recovery 
was achieved through the addition of 60% acetonitrile/0.2% trifluoroacetic acid to each plug 
for 10min at 37
o
c with gentle agitation. Supernatants were added to the peptide pool. The 
sample was dried through vacuum centrifugation and concentrated peptide fractions were then 
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suspended in mass spectrometry-grade distilled water and 0.1% formic and spun down 
through spin filter and added to LC-MS viles for identification by ion trap LC-MS  analysis. 
Separation of peptides was performed with a nanoflow Agilent 1200 series system (Agilent 
Technologies). Mobile phases used were A: 0.1% formic acid, B: 50% acetonitrile and 0.1% 
formic acid. Five microliters of sample were loaded into the enrichment at a capillary flow 
rate set to 2ul/min with a mix of 0.1% formic acid and 50%acetonitrile and formic acid at a 
ratio of 19:1. The cappilary voltage was set to 1800V. Tryptic peptides were eluted with a 
linear gradient of 10-90% solvent B over 15min with a constant nano pump flow of 
0.60ml/min. A five min post time of solvent A was used to remove any sample carryover. 
Database searches were carried out with Mascot MS/MS Ion search(Matrix Science, London, 
UK) under the following parameters: (i) two missed cleavages by trypsin, (ii) mass tolerance 
of precursor ions± 2.5 Da and product ions ± 0.7 Da, (iii) carboxymethylated cysteins fixed 
modification and (iv)oxidation of methionine as variable modification. Searches used 
“musculus” as taxonomic categorgy unless otherwise stated and used the NCBInr database 
release: 20100212. Identification of protein of interest was accepted when Mascot score > 49 
was obtained with 2 or more peptides matched and molecular weight and pI matched the 
master gel. By choosing a score of greater than 49 we are 95% confident our match is correct. 
 
2.2.11.1 Liquid Chromatography-Mass Spectrometry of on-membrane digestion. 
Recovered peptides were analyzed on an Agilent 6340 LC-MS instrument (Agilent 
Technologies, Santa Clara, CA, USA) on a gradient of 5 to 100% acetonitrile/0.1% formic 
acid for 142min.  Separation of peptides was performed with a nanoflow Agilent 1200 series 
system equipped with a Zorbax 300SB C18 analytical reversed phase column (5mm, 
43mmx75mm) using high-performance liquid chromatography (HPLC)-chip technology. 
Mobile phases used were A(0.1%formic acid) and B(90%acetonitrile/0.1% formic acid). 
Samples(5ml) were loaded into the enrichment at a capillary flow rate set to 4ml/min with a 
mix of A and B at a ratio 19:1. Tryptic peptides were eluted with a gradient of 5 to 34% 
solvent B over 1min, 34 to 36%solvent B over 40min, 36 to 38% over 1min, 38 to 40%over 
80min, 40 to 90% over 5min, 90 to 100% for 5min and 100 to 5% over 5min with a constant 
nano pump flow of 0.60ml/min. A 5min post time of solvent A was used to remove any carry 
over. The capillary voltage was set to 2000V. The flow and temperature of the drying gas 
were 4L/min and 300
o
 respectively. Identified peptides were used to determine the protein 
species present in the distinct protein bands. Database searches were carried out with Mascot 
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tandem mass spectrometry (MS/MS) ion search (Matrix Science, London, UK, NCBI 
database) with the same parameters as discussed in section 2.2.11 with “mammailia” as 
taxonomic categorgy.  
 
2.2.12 On-membrane digestion 
Protein bands were excised from membranes, placed in small eppendorf tubes, destained, and 
washed five times with distilled water. Nitrocellulose bands were then blocked with 0.5% 
polyvinylpyrrolidone (PVP-40) at 37
o
C for 37min with gentle shaking. Nitrocellulose bands 
were susequently washed five times with distilled water. Treatment with trypsin was 
performed by an optimised method (Doran et al. 2004). Membrane bands were digested 
overnight at 37
o
C in 100ml of working trypsin solution.       Trypsin-generated peptides were 
obtained by removing supernatants from digested nitrocellulose bands. Further recovery was 
achieved by adding 30%acetonitrile/0.2%trifluoroacetic acid to the gel plugs for 10min at 
37
o
c with gentle agitation. Resulting supernatants were pooled with the initially recovered 
cohort of peptides following trypsin digestion. Further peptide recovery was achieved through 
the addition of 60%acetonitrile/0.2%trifluoroacetic acid to each plug for 10min at 37
o
c with 
gentle agitation. Supernatants were added to the peptide pool. The sample was dried through 
vacuum centrifugation and concentrated peptide fractions were then suspended in mass 
spectrometry-grade distilled water and 0.1% formic and spun down through 22-mm cellulose 
spin filter tubes to remove any membrane particles, and then aliquoted to LC-MS viles for 
identification by ion trap LC-MS  analysis. 
 
2.2.13 Western Blotting 
Gel electrophoresis and transfer was carried out with a Mini-Protean II electrophoresis and 
transfer system from Bio-Rad Laboratories (Hemel-Hempstead). Muscle proteins were 
transfered to nitrocellulose membranes for 70 min at 100 V at 4
o
C in transfer buffer (28.28g 
Glycine, 6.56g Tris, 1600 ml dH2O and 400 ml Methanol). Efficiency of transfer was 
evaluated by Ponsceau S-Red staining of membranes, followed by de-staining with phosphate 
buffered saline (PBS) (50mM sodium phosphate, 0.9% (w/v) NaCl, pH7.4). Membranes were 
placed in blocking sloution (5% (w/v) fat free milk powder in PBS) for 60 min at room 
temperature. Membranes were then incubated with primary antibody appropriately diluted 
(see table 2.2) with blocking solution for 3 h at room temperature. Membranes were then 
washed 4X 10 min washes: 2 X 10 minutes in blocking solution and 2 X 10 min in PBS. 
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Membranes were then incubated with appropriate dilution peroxidase-conjugated secondary 
antibody for 60 min at room temperature. The membranes were then washed with 4 X 10 min 
washes: 2 X 10 min with blocking solution and 2 X 10 min in PBS. Immuno-decorated bands 
were visualised by the enhanced chemiluminescence method using chemiluminescence 
substrate from Roche Diagnostics (Mannheim, Germany).  
 
2.2.14 Statistical Analysis 
Statistical analysis of densitometry results from immunoblots was performed using ImageJ 
(NIH, Bethesda, Maryland, USA). Statistical analysis of densitometric results from 
immunoblots were carried out using Graphpad prism statistical software (Graphpad software 
Inc.). Throughout this project a probability value of 0.05 was used within student’s t-test. By 
choosing this our data is significant with 95% confidence.  
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3. RuPBs analysis of Gastrocnemius muscle proteome of the myotonic animal model: 
MTO*5J 
 
3.1 Introduction 
Myotonia is a symptom of various genetic and aquired skeletal muscle disorders and is 
characterised by hyperexcitability of muscle sarcolemma. Skeletal muscle hyperexcitability is 
caused by either lowered Cl
-
 conducatance (myotonias) or prolonged activity of Na
+
 channels 
(paramyotonia). Both disorders belong to a distinct group of skeletal muscle disorders called 
ion channelopathies. Ion channelopathies are characterised by recurrent patterns of mutation 
in ion channels including: Cl
-
, Na
+
, K
+
 and Ca
2+
-channels.  Myotonias can be classified as 
dystrophic, where multiple tissues are affected, or non-dystrophic where it is only skeletal 
muscle that is affected. Nondystrophic myotonias are closely related to ion channel 
dysfunction, and are classified as channelopathies affecting muscle-specific Cl
-
- or Na
+
-
channels (Planells-Cases et al. 2009). Mutations in the gene encoding the muscle Na
+
-channel 
are associated with paramyotonia congenita, potassium-sensitive myotonia and hyperkalemic 
periodic paralysis with myotonia. In contrast, nondystrophic chloride channelopathies are 
responsible for myotonia congenita, recessive Becker myotonia and dominant Thomsen 
myotonia (Fahlke, 2000).  
 Genetic animal models of neuromuscular diseases are widely used for studying the molecular 
pathogenesis and secondary effects of disease. For this study gastrocnemius muscle from 
MTO*5J mice was used to represent myotonic muscle. The characterization of the new allele 
MTO*5J at Clc1 locus of mice allows longer survival of homozygous animals as compared to 
other myotonic mouse mutants ADR and MTO. The affected mice do not produce 
immunologically demonstrable CLC-1 protein and they display central nuclei in their muscle 
fibers indicating ongoing regeneration. 
 This chapter attempted broad proteomics-based analysis to determine changes caused by 
single mutation by means of a changed physiological activity of the organ in which this gene 
is expressed, skeletal muscle. Protein extracts were obtained from gastrocnemius muscle from 
4 control mice and from 4 MTO*5J mice. Protein extracts were separated in the first 
dimension by their isoelectric point and in the second dimension based on their molecular 
weight. Separated proteins were then visualized using the fluorescent dye RuPBs (ruthenium 
II tris[bathophenanthroline disulfonate]) was used. RuBPs is a ruthenium-based metal chelate 
stain and was first described as an in gel protein stain by Rabilloud in 2001.  
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3.2 Results 
 
3.2.1. 2-D gel electrophoretic analysis of gastrocnemius muscle proteome of myotonic animal 
model: MTO*5J 
Crude soluble protein extracts were obtained from 11-week old control and MTO*5J mouse 
gastrocnemius muscle and were separated first by one-dimensional gel electrophoresis to 
check equal loading (see Figure 3.1). From Figure 3.1 it is difficult to determine changes in 
protein expression of one particular protein therefore in order to gain better separation protein 
extracts were separated by standard 2-D gel electrophoresis. Isoelectric focusing was 
performed in the pH ranges of pH4.0-7.0 and pH6.0-11.0 and was followed by SDS-PAGE 
electrophoresis covering a molecular mass range of approximately 10kDa to 220kDa. RuPBs 
stained protein gels are shown in Figure 3.2. Progenesis Same Spots software version 3.2.3 
from NonLinear Dynamics (Newcastle Upon Tyne, UK) was employed for the statistical 
evaluation of changes in individual protein spots in diseased versus control. Protein spots with 
altered expression were then identified by mass spectrometry. 
  47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Silver stained 1-Dimensional gel 
Shown is silver stained 1-D gel electrophorectically separated total gastrocnemius muscle 
extracts from control (lanes 2,4,6 and 8) and MTO*5J (lanes 3,5,7 and 9). A total of 10mg of 
protein is loaded in each lane and 5ml molecular weight standard (lane 1). 
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Figure 3.2 2-D gel electrophoretic analysis of normal versus myotonic gastrocnemius 
muscle 
Shown are 2-D gels electrophoretically separated total crude soluable extracts in both pH 
ranges from control (A;pH4-7,B;pH6-11) and myotonic (C;pH4-7,D;6-11) from MTO*5J 
mice. 2-D gels were stained with RuBPs stain. The pH values of the first dimension and 
molecular mass standards of the second dimension are indicated on the top and on the left of 
the panels respectively. 
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3.2.2 Differential protein expression pattern in myotonic animal model MTO*5J 
Two-dimensionial spot patterns were compared across 8 slab gels using Progenesis Same 
Spot software. In total 950 clearly separated protein spots were identified by RuPBs staining. 
A total of 12 protein spots with changed abundance were identified in the MTO*5J mouse 
model of mild myotonia. The proteins with changed abundance ranged in pI from 4.8 (myosin 
light chain fast MLC2f) to 9.2 (F1-ATPase synthase) and ranged in molecular mass from 19 
kDa (myosin light chain) to 61 kDa (heat shock protein Hsp60). Table 3.1 summarizes 
information gained from proteomic profiling of MTO*5J mouse model. It gives information 
on protein name and number so that it can be correlated to the numbering in the 2-D MTO*5J 
master gel shown in figure 3.3. Table 3.1 shows fold changes, percentage coverage, 
isoelectric point and molecular weights of identified proteins. Table 3.1 lists 4 proteins being 
decreased and 8 proteins being increased in MTO*5J samples. While myosin heavy chain 
MHC1 (spot 1), myosin light chain MLC2f (spot 2), T complex protein 1 (spot 3) and heat 
shock protein Hsp60 (spot 4) were shown to be reduced, protein spots representing troponin 
TnTf (spots 6 and 12), triosephosphate isomerase (spot 11), desmin (spot 10), F1-ATP 
synthase (spot 9), NADH dehydrogenase (spot 8), heat shock protein Hsp27 (spot 7) and 
superoxide dismutase (spot 5) were found to be increased in MTO*5J specimens.   
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Figure 3.3 2-D Master gel of MTO*5J mouse model of mild myotonia 
Shown is a 2-D master gel of the MTO*5J gastrocnemius muscle proteome separated in the pI 
ranges pH4-7 (A) and pH6-11 (B). Proteins with a drastically altered expression that have 
been identified by LC/MS are numbered 1-12. A total of 8 protein changes were identified in 
the pH 4-7 (A) range and 4 changes in the pH 6-11 (B) range. Table 3.1 shows details of fold 
changes in myosin heavy chain (pI 5.61; 22 kDa), myosin light chain phosphorylatable, fast 
(pI 4.82; 19 kDa), T complex protein 1 (pI 5.82; 60 kDa), Hsp 60 (pI 6.07; 61 kDa), 
superoxide dismutase SOD2 (pI 8.67; 24 kDa), troponin T, fast (pI 5.98; 30 kDa), Hsp 27 (pI 
6.45; 23 kDa), NADH (pI 6.67; 30 kDa), F1-ATPase synthase (pI 9.16; 28 kDa), desmin (pI 
5.21; 53 kDa), triosephosphate isomerase (pI 5.62; 22 kDa) and troponin T, fast (pI 6.18, 30 
kDa). The pH values of the first dimension and molecular mass standards of the second 
dimension are indicted on the top and on the left of the panel respectively. 
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Table 3.1:  List of proteins that exhibit a changed abundance in myotonic MTO*5J versus normal gastrocnemius muscle. 
Spot 
no. 
Name of identified protein Protein 
accession no.
* 
pI Molecular 
mass (kDa) 
Sequence 
coverage 
(%) 
Mascot 
score 
** 
Peptides 
matched 
Fold 
change 
*** 
Anova 
1 Myosin, heavy chain, MHC1, 
skeletal muscle 
gi|187956263| 5.61 224136 33 476 22 -5.8 1.50E-02 
2 
Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|7949078| 4.82 19059 5 100 34 -3.6 5.00E-03 
3 T complex protein 1 gi|228954| 5.82 60960 16 368 41 -3.6 1.40E-02 
4 
Heat shock protein Hsp60 gi|51766670| 6.07 61190 23 461 43 -1.4 3.00E-03 
5 
Superoxide dismutase SOD2, 
mitochondrial gi|17390379| 8.67 24244 5 177 24 2.4 9.00E-03 
6 Troponin TnT, fast gi|2340064| 5.98 30691 4 98 28 2.5 1.10E-02 
7 
Heat shock protein Hsp27 gi|424143| 6.45 22945 10 152 49 2.9 1.30E-02 
8 
NADH dehydrogenase FeS 
protein 3, mitochondrial gi|58037117| 6.67 30305 12 315 36 2.9 3.85E-04 
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9 
ATP synthase, mitochondrial 
F1 complex gi|122889678| 9.16 2864 11 520 36 3.0 2.00E-03 
10 
Desmin gi|33563250| 5.21 53523 27 582 59 3.4 1.00E-02 
11 
Triosephosphate isomerase  gi|1864018| 5.62 22720 12 531 76 3.7 1.40E-02 
12 Troponin TnT, fast gi|2340068| 6.18 30297 9 347 30 6.0 1.20E-02 
 
*NCBInr Database, release 20100212 
** The mascot score has a 95% confidence level if >49. 
*** Myotonic versus normal muscle tissue 
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3.2.3 Immunoblot analysis of potential biomarkers of Myotonia 
In order to verify alterations in abundance of skeletal muscle proteins and to confirm our 
proteomic profiling of myotonic muscle several proteins were selected for immunoblotting 
studies. As shown in Figure 3.4 A-C, the decrease in triosephosphate isomerase (TPI), myosin 
light chain phosphorylatable (MLC-phospho) and myosin light chain 2 (MLC-2) can be seen. 
Although the statistical analysis of immuno-decorated bands showed no significance the 
analysis showed a slight decrease of the proteins in myotonic muscle. As shown in Figure 3.5 
the decrease in myosin heavy chain fast in myotonic muscle was clearly confirmed by 
immunoblot analysis. This statistically significant difference in expression correlates with the 
proteomic findings listed in Table 3.1. As previous studies on more pronounced myotonic 
muscle has described a variety of expression changes in MHC isoforms (Agbulut et al. 2004), 
it was therefore interesting to see was this change similar in our new allele mto*5j. The 
decrease of myosin heavy chain fast isoform in MTO*5J myotonic muscle is shown in Figure 
3.5 (A). The immunoblotting of fiber type-specific markers of regulatory elements of muscle 
relaxation Ca
2+
 isoforms SERCA1 and SERCA2 is shown in Figure 3.6. The immunoblotting 
of the slow isoform SERCA2 (B;F) showed a significant increase in myotonic muscle 
whereas the fast isoform SERCA1 (A;E) showed a decrease in expression although the 
statistical analysis was not significant. As shown in Figure 3.6 (C, G) immunoblotting 
analysis was also carried out on the myoglobin protein and showed a slight increase in the 
myotonic muscle. Similarly in Figure 3.6 (D, H) immunoblotting was carried out on the high-
affinity Ca
2+
-binding protein parvalbumin. Previously published immunoblot work on more 
pronounced myotonic muscle showed a decrease in parvalbumin (Jockusch et al. 1988) and so 
it was of interest to see did the mto*5j allele show a similar decrease in parvalbumin. As 
illustrated in Figure 3.6 (D, H) parvalbumin was marginally decreased in MTO*5J myotonic 
muscle. Figure 3.7 shows immunoblotting of alpha-dystroglcan as a loading control. The data 
presented here clearly verifies alterations in abundance of some of proteins from our 
proteomic profiling of myotonic muscle. 
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Figure 3.4 Immunoblot analysis of triosephosphate isomerase, myosin light chain 
phosphorylatable and myosin light chain-2 in myotonic muscle. 
Shown are the imuno-decoration bands of nitrocellulose replicas of 1-D gels. Antibodies were 
directed against triosephosphate isomerase (A), myosin light chain phosphorylatable (B) and 
myosin light chain-2 (C). The immuno-decorated bands from normal and myotonic muscle 
were statistically evaluated using unpaired Student’s t-test (n=4;p*<0.05) and is graphically 
shown in panels (D), (E) and (F).  
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Figure 3.5 immunoblot analysis of myosin heavy chain fast and myosin heavy chain slow 
Shown is the immuno-decoration of nitrocellulose bands of 1-D gels. Antibodies were 
directed against myosin heavy chain fast (A) and myosin heavy chain slow (B). The 
comparative  immuno-decorated bands were statistically evaluated using an unpaired 
Student’s t-test (n=4;*p<0.05) and are shown graphically in panels (C) and (D). 
 
  56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Immunoblot of SERCA1, SERCA2, Myoglobin and parvalbumin in myotonic 
muscle. 
Shown is the immuno-decoration of nitrocellulose bands from 1-D gel. Antibodies were 
directed against SERCA1 (A), SERCA2 (B), myoglobin (C) and parvalbumin (D). 
Comparative immuno-decorated bands were statistically evaluated using unpaired Student’s t-
test (n=4;*p,0.05) and are graphically shown in panels (E), (F), (G) and (H).  
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Figure 3.7 Immunoblot of alpha dystroglycan in myotonic muscle.  
Shown is the immuno-decorated nitrocellulose bands from 1-D gel. Antibodies were directed 
against alpha dystroglycan (B). Comparative immuno-decorated bands were statisically 
evaluated using unpaired Student’s t-test (n=4) and is graphically shown in panel (A). 
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3.3 Discussion  
Two dimensional gel electrophoresis with RuPBs staining revealed 12 protein spots with 
altered expression in MTO*5J myotonic muscle. Of these 12 spots 4 showed decrease in 
expression and 8 with an increase in expression. These 12 proteins were identified by Liquid 
chromatography mass spectrometry and are involved in multiple functions in the muscle cell 
ranging from muscle contraction to muscle metabolism. These proteins will now be discussed 
in detail. 
 
3.3.1 Contractile proteins 
The contractile units of skeletal muscle are composed of thick and thin filaments. Skeletal 
muscle myosin forms a hexameric structure consisting of 2 myosin heavy chains (MHCs) and 
2 myosin light chains (MLCs) and make up thick filaments (Clark et al. 2002). Thin filaments 
are composed of actin and accessory proteins troponin and tropomyosin. Molecular coupling 
between the myosin head structure and actin filaments, in the prescence of ATP causes sliding 
of the thin filaments past thick filaments resulting in sarcomeric shortening and muscle 
contraction. In this study two contractile proteins were found to have a decreased abundance 
in MTO*5J gastrocnemius muscle, myosin heavy chain MHC1 (spot 1) and myosin light 
chain MLC2f  (spot 2). MHC1 was found to have a 5.8 fold decrease in MTO*5J 
gastrocnemius tissue. MHC1 is part of the MHCs isoforms found in fast muscle fibers. 
MLC2f was shown to have a 3.6 fold decrease in MTO*5J gastrocnemius tissue compared to 
control tissue. MLC2f is the regulatory light chain found in skeletal muscle it is associated 
with the MHC neck region of the myosin molecule.  
Previous work on the more profoundly affected ADR mouse showed a drastic reduction in 
MHC IIB (Agbulut et al. 2004) which supported the idea that the shift in MHC fast observed 
in ADR mice was caused by the hyperexcitability of muscle. Agbulut and colleagues (2004) 
concluded that the hyperexcitability of the myotonic muscle leads to unschelduled episodes of 
trains of action potentials. Immunoblotting of MTO*5J gastrocnemius muscle agrees with this 
previous work as seen in Figure 3.5. MHC fast showed a significant decrease in MTO*5J 
muscle whereas MHC slow showed a significant increase.  Similarly previous proteomic 
studies have shown that isoform changes in MLCs represent reliable markers of muscle 
transformation (Reininghaus et al. 1988). Donoghue and co-workers (2007) carried out  
chronic low-frequency stimulation of fast rabbit muscle and showed it triggers a significant 
decrease in various MLCf molecules and an increase in slower counterparts. Immunoblotting 
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shown in Figure 3.4 agrees with a significant decrease in MLC2 isoform. Although the 
statistical analysis of Western blotting showed no significant difference in the abundance of 
MLC2f between MTO*5J and control gastrocnemius muscle the overall analysis indicated a 
trend towards increased expression of slower MHC isoforms and a decrease in fast isoforms 
of MHC and MLC2. The effect of repetitive firing of action potentials seen in myotonic 
muscle seems to mirror the effect of chonic low-frequency stimulation on fast muscle i.e. 
muscle transformation from fast isoforms to their slower counterparts.   
 Troponin I (spot 3) was found to be decreased in MTO*5J muscle with a 3.6 fold change. 
The troponin compex is a set of three regulatory proteins of muscle contraction (Tobacman 
1996). As described previously it is a component of the thin filaments along with actin and 
tropomyosin. Troponin I binds actin to hold the troponin-tropomyosin complex in place. A 
decrease abundance of troponin could affect the integrity of the contractile apparatus in 
myotonic muscle.  
 The changes seen in contractile proteins in MTO*5J gastrocnemius tissue mirror those seen 
during electrostimulation-induced muscle transformation. Changes in the accessory protein 
may indicate contractile apparatus remodeling due to myotonia. 
 
3.3.2 Metabolic enzymes 
Metabolism is responsible for the production of energy in the form of ATP. Glycolysis is the 
process used to convert glucose into pyruvate, with the generation of energy in form of 
NADH and ATP along the pathway. It is an anerobic process and is main metabolic pathway 
in fast-twitch fibers (Peter et al. 1972). Respiration is carried out in the mitochondrion 
through the electron transport chain and the Krebs cycle. In this study four enzymes involved 
in metabolism have shown altered abundance in MTO*5J gastrocnemius muscle. 
Triosephosphate isomerase (TPI, spot 11) was found to have a 3.7 fold increase in MTO*5J 
muscle. Figure 3.4 shows a slight decrease in TPI however statistical analysis showed no 
significant difference. TPI rapidly interconverts dihydroxyacetone phosphate and D-
glyceraldehyde-3-phosphate (Trentham et al. 1969). D-glyceraldehyde-3-phosphate is further 
used in the glycolysis pathway. There are five complexs altogether that result in the 
production of ATP in respiration. NADH dehydrogenase (spot 8) showed a 2.9 fold increase 
in MTO*5J muscle. NADH dehydrogenase (complex I) is an enzyme located in the inner 
membrane of mitochondria. It is responsible for the entry of electrons into the electron 
transport chain by moving electrons from NADH to quinone. Succinate dehydrogenase 
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(SDHA) is part of complex II and functions in oxidative phosphorylation chain but also in the 
citric acid cycle. Ubiquinol-cytochrome c reductase core protein 1 is a subunit of complex III 
and is responsible for the movement of electrons from quinone to cytochrome c. Together the 
above complexes pass electrons along the electron transport chain and are also responsible for 
the export of protons into the intermembrane space creating a proton gradient. H
+
 transporting 
ATP synthase (complex V) pumps electrons in the opposite direction allowing the formation 
of ATP a cellular store of energy. The increased abundance of NADH in myotonic muscle 
might result in a higher rate of ATP production by oxidative metabolism. The use of oxidative 
metabolism for ATP production is indicative of a slower fiber population. 
 The 3-fold increase in mitochondrial ATP synthase (spot 9) in MTO*5J muscle also agrees 
with the suggestion that there is a reduction in the utilization of glucose and increase in 
mitochondrial metabolism. This increase in mitochondrial metabolism increases oxidative 
stress as mitochondria are the biggest producers of free radicals. Evidence of this increase in 
oxidative stress in myotonic muscle is see by the 2.4 fold increase in superoxide dismutase 
(SOD, spot 5). SOD destroys radicals which are normally produced by the mitochondria. 
Similar evidence of mitochondrial metabolism is seen in the striking red colour of myotonic 
muscle which was first described by Watkins and Watts (1984). Immunoblotting for the 
oxygen carrying protein myoglobin showed a slight increase in the MTO*5J gastrocnemius 
muscle. It is interesting that the increase in myoglobin has also been reported to occur in fast 
muscle following chronic electro-stimulation (Donoghue et al. 2007). This finding agrees 
with the idea that myotonic runs mirror the effect that electro stimulation has on fast muscle 
tissue.  
 
  61 
3.3.3 Muscle transformation 
Differences in muscle protein isoforms reflect distinct biological adaptations to specific 
functional demands. Antibody labeling shown in Figure 3.6 confirmed a switch from the 
SERCA1 isoform of the sarcoplasmic reticulum Ca
2+
-pump to its SERCA2 form. Relaxation 
of skeletal muscle is assisted by the action of SERCA where calcium is pumped back into the 
SR. There are five primary SERCA isoforms that are encoded by three separate genes (Rossi 
et al. 2006). The ATP2A1 gene encodes the SERCA 1 isoform, this gene can be spliced into 
adult SERCA 1a and neonatal SERCA 1, similarly ATP2A2 can be spliced to form adult 
SERCA 2a and neonatal SERCA 2b (Rossi et al. 2006). SERCA 1a is the principal isoform 
found in fast-twitch skeletal muscle whereas SERCA 2a is the principal isoform found in 
slow-twitch skeletal muscle. The tissue specific expression pattern of each different SERCA 
isoform indicates the functionally distinct properties of skeletal muscle fibers. Immunoblot 
analysis (Figure 3.6) showed a significant increase in the slow SERCA 2 isoform however 
analysis of the fast SERCA 1 isoform showed no significant difference in MTO*5J 
gastrocnemius muscle. Increases in SERCA 2 agree with fiber transformation to a slower 
population due to myotonia.  
 
3.3.4 Other proteins 
As well as proteins involved in muscle contraction, metabolism and calcium uptake  a number 
of other proteins were found to have an altered abundance in MTO*5J  gastrocnemius muscle. 
 Of these heat shock porteins Hsp 60 (spot4) and Hsp 27 (spot 7) were found to be decreased 
and increased in myotonic muscle by 1.4 and 2.9 fold change respectively.  Heat shock 
proteins are a set of highly conserved proteins that are sythesised in response to certain 
environmental and physiological conditions (Locke and Noble 1995). They function in 
protein folding, import and translocation. Hsp 60 is localised in the mitochondria and 
facilitates the folding and assembly of proteins as they enter the mitochondrion and stabilises 
preexisting proteins under stress (Lui and Steinacker 2001). Hsp 27 is localised in the cytosol 
under unstressed conditions and translocates inside the nucleus during stress. The major 
functions of Hsp27 include stabilisation of microfilaments and cytokine signal transduction 
(Lui and Steinacker 2001). Increases in these proteins not only agrees with muscle 
transformation in myotonic muscle but also suggests MTO*5J muscle is under cellular stress 
from hyperexcitabilty of the plasma membrane that causes muscle stiffness. Perhaps the 
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increase in Hsp27 in myotonic muscle functions to aid in the stabilisation of contracted 
muscle filaments.  
 An increase was also seen in the intermediate filament protein desmin. Intermediate filament 
proteins are important for the structural integrity of the muscle cell they help provide 
elasticity within the contractile fibers. The increase in expression of  desmin maybe due to the 
sustained contraction in myotonic muscle after voluntary contraction. 
 Previous studies on the more profoundly effected ADR mouse by Jockusch and colleagues 
(1988) demonstrated a reduction in the Ca
2+
-binding protein parvalbumin. A considerably less 
pronounced reduction of parvalbumin was observed in the mild MTO8*5J phenotype (Figure 
3.6).  
 
3.4 Conclusion 
In this study we have analysed the myotonic mouse MTO*5J using fluorescent 2D gel 
electrophoresis and mass spectrometry to identify novel protein markers of the myotonia-
related changes. Mild myotonia appears to trigger changes in contractile apparatus, cellular 
processes and muscle energy metabolism. Altered protein expression in MTO*5J  were 
comparable with changes in fast skeletal muscle following chronic electro-stimulation. An 
overall shift from fast-to-slow isoforms in MHC and SERCA and an increase in 
mitochondrial metabolism markers such as mitochondrial ATPase and superoxide dismutase 
suggest that myotonia triggers a glycolytic-to-oxidative transformation process in myotonic 
fast muscle.  
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4. Comparative analysis of altered protein expression in myotonic animal models: ADR 
versus MTO. 
 
4.1 Introduction 
Genetic animal models of neuromuscular disorders are widely used for studying the molecular 
pathogenesis of inherited disorders, evaluating effects of drug treatment on disease 
progression and testing novel therapeutic stategies. In the case of myotonia research 
manifestation and molecular basis of the disease has been clarified by analysis of well 
established myotonic mouse mutants’ arrested development of righting response (ADR) and 
myotonia (MTO). The ADR mutant is caused by insertional mutation (allele adr) whereas the 
MTO mutant is due to a nonsense mutation in the chloride channel gene locus Clc1 on 
chromosome 6. ADR and MTO mice are both genocopies and phenocopies of human 
congenital myotonia. In human myotonia both recessive (Becker type) and dominant 
(Thomsen type) mutations at gene locus CLCN1 on chromosome 7 have been identified. In 
contrast to the MTO*5J animial, ADR and MTO show a more pronounced phenotype 
displaying more severe symptoms, weight loss and reduced life span. Similar to the mto*5j 
mutation, adr and mto mutations are null mutations and result in complete deletion of the 
CLC-1 protein. Previous histochemical work on the ADR animal model show a variety of 
biochemical changes in affected muscles (Jockusch et al. 1988). Many of these biochemical 
changes were reminiscent of those observed in chronic low-frequency stimulated fast muscle
 
which involves a fiber type shift from fast-glycolytic white muscle to fast-oxidative red 
muscle (Pette and Staron 2000). In long-term electrostimulated fast rabbit muscles, fiber 
transitions eventually result in a slow-oxidative muscle phenotype that is reflected by 
extensive fast-to-slow switches in protein isoforms (Donoghue et al. 2007). In myotonic 
muscles, transformations are well documented by the alterations in the isoform expression 
pattern of slow and heavy chains of muscle myosins. For example, hyperexcitability triggers a 
reduced phosphorylation of the fast myosin light chain MLC2f (Jockusch et al. 1988). 
 
A 
lower concentration of myosin heavy chain isoform MyHC-IIB has also been shown in 
myotonic fast muscles (Agbulut et al. 2004).   
In this chapter we carried out a comparative proteomic survey of ADR versus MTO muscle 
preparations. Similar to MTO*5J myotonic gastrocnemius muscle analysis, gastrocnemius 
muscle from the hind leg from four ADR mice and four MTO mice versus gastrocnemius 
from four control mice was used in this study. Crude soluble protein extracts were separated 
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first by one dimensional gel electrophoresis in order to confirm equal loading (see Figure 4.1). 
As seen in Figure 4.1 separation by one dimensional gel electrophoresis it is difficult to 
determine changes in single protein species, therefore crude protein extracts were separated 
by 2-DE in the pH ranges of pH4.0-7.0 24cm strips and pH6.0-11.0 18cm strips in the first 
dimension and then separated in the second dimension based on their molecular weights. 
Separated proteins were visualized using the fluorescent RuPBs stain. 
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4.2 Results 
4.2.1 1-D gel electrophoresis of gastrocnemius muscle proteome of ADR and MTO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Silver stained 1-Dimensional gels  
Shown are silver stained 1-D gels of ADR (A) gastrocnemius muscle (lanes 3,5,7 and 9) and 
control gastrocnemius muscle (lanes 2,4,6 and 8). The 1-D gel of MTO (B) gastrocnemius 
muscle (lanes 3,5,7 and 9) and control (lanes 2,4,6 and 8). A total of 5mg of protein was 
loaded per lane and 5ml of molecular weight marker is shown in gels A and B (lane 1). 
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Figure 4.2 Two-Dimensional gel electrophoresis analysis of myotonic muscle versus 
control muscle 
Shown are 2-D gel electrophoretically separated gastrocnemuis muscle extracts of control 
pH4-7(A) and pH6-11(B), MTO pH4-7 (C) and pH6-11 (D) and ADR pH4-7 (E) and pH6-11 
(F) stained with RuPBs stain. The pH-values and molecular weight standards (kDa) are 
indicated at the top and left of the panels respectively. 
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4.2.2 Differential protein expression pattern in myotonic animal model MTO 
Two-dimensional gel electrophoresis resulted in the identification of 42 muscle protein spots 
with a changed abundance in the MTO mouse. A representative master gel with 
electrophoretically separated gastrocnemius muscle proteins is shown in Figure 4.3. Muscle 
proteins with a changed concentration covered a pI-range from approximately 4.6 
(tropomyosin) to 7.6 (cofilin) and ranged in molecular mass from apparent 19 kDa (myosin 
light chain) to 84 kDa (heat shock protein Hsp90). Table 4.1 summarizes the results of the 
mass spectrometric identification of the 42 protein species from MTO muscle tissue and 
combines data from both pH 4.0-7.0 and pH 6.0-11.0 gels. The majority of identified proteins 
in MTO preparations were shown to be constituents of major metabolic reactions, the 
contractile machinery, the cellular stress response and cell signaling pathways. An increased 
concentration was shown for 16 muscle proteins and 26 proteins were found to be decreased 
in MTO muscle. The protein species with the strongest reduction was the phosphorylatable 
fast MLC2f isoform of myosin light chain. Decreased proteins were identified as MLC2f 
(spots 1, 7, 8, 10, 14, 17, 20, 24), DJ-1 protein (spot 2), heat shock protein beta-7 (spot 3), 
myosin-binding protein H (spot 4), T Complex protein 1 (spot 5), myosin light chain MLCs 
(spot 6), creatine kinase (spot 9), ribonuclease/angiogenin inhibitor (spot 11), glycogenin 
9spot 12), tropomyosin (13), heat shock protein Hsp-2 9spot 15), myosin light chain MLC3 
(spot 16), glyceraldehydes-3-phosphate dehydrogenase (spot 18), F-actin capping protein 
(spot 19), triosephosphate isomerase (spot 21), protein disulfide isomerase (spot 22), pyruvate 
kinase (spot s 23 and 25) and sepiapterin reductase (spot 26). In contrast, 
phosphoglucomutase (spot 42) was shown to be the enzyme with the highest fold increase in 
MTO muscle. In addition, succinate dehydrogenase (spot 42), Actg2 protein (spot 40), cofilin 
(spot 39), troponin TnTf (spot 38), alpha actin (spots 36 and 37), mitochondrial NADH 
dehydrogenase (spot 35), heat shock protein Hsp90 (spot 34), albumin (spot 33), cytosolic 
malate dehydrogenase (spot 32), 14-3-3 protein (spot 31), tubulin (spot 30), UTP-glucose-1-
phosphate uridyltransferase (spot 29), one specific subspecies of MLC2f (spot 28) and 
dihydrolipoamide-S-acetyltransferase (spot 27) were increased in MTO gastrocnemius 
muscle.  
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Figure 4.3 2-D master gel of the MTO myotonic muscle proteome 
Shown are the 2-D master gels of the myotonic gastrocnemius muscle proteome of the MTO 
animal model. Proteins were separated in the pI ranges of pH4-7 (A) and pH6-11 (B). 
Proteins with an altered abundance and have been identified by LC/MS are numbered 1-42. A 
total of 37 proteins with changed abundance were identified in the pH 4-7 (A) range and 5 
protein changes were identified in the pH 6-11 (B) range. 
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Table 4.1 List of identified protein species that exhibit a drastic change in MTO gastrocenmius myotonic muscle versus normal gastrocnemius 
muscle. 
 
Spot 
no. 
Name of identified protein Accession no.
* 
pI Molecular 
mass (kDa) 
Peptides 
matched 
Mascot 
score** 
Coverage 
(%) 
Fold 
change*** 
Anova 
1 Myosin light chain MLC2f, 
phosphorylatable, fast 
muscle gi|7949078| 4.82 19059 7 129 48 -18.7 2.30E-04 
2 DJ-1 protein gi|55741460| 6.32 20240 14 191 76 -17.7 3.50E-04 
3 Heat shock protein beta-7 gi|31542970| 5.95 18681 11 218 78 -17.2 1.00E-03 
4 Myosin-binding protein H  gi|56676318| 5.75 53073 10 150 34 -10.6 1.00E-03 
5 T complex protein 1 gi|228954| 5.82 60960 16 368 41 -10.3 2.19E-04 
6 Myosin light chain MLC2, 
cardiac/slow gi|153791853| 4.86 18852 10 113 66 -9.8 2.00E-03 
7 Myosin light chain MLC2f, 
phosphorylatable, fast 
muscle gi|7949078| 4.82 19059 7 126 48 -9.8 9.00E-03 
8 Myosin light chain MLC2  gi|199985| 4.71 18870 14 216 87 -9.3 5.00E-03 
9 Muscle creatine kinase gi|6671762| 6.58 43250 12 393 34 -8.8 9.00E-03 
10 Myosin light chain MLC2f, gi|7949078| 4.82 19059 9 157 53 -8.0 3.00E-03 
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phosphorylatable, fast 
muscle 
11 Ribonuclease/angiogenin 
inhibitor 1 gi|31981748| 4.69 51524 6 93 17 -7.8 1.62E-04 
12  Glycogenin-1  gi|7305121| 5.06 37610 6 114 24 -6.5 6.08E-04 
13 Tropomyosin, beta chain gi|11875203| 4.66 32933 12 235 34 -6.2 2.00E-03 
14 Myosin light chain MLC2f, 
phosphorylatable, fast 
muscle gi|7949078| 4.82 19059 4 49 18 -6.1 2.68E-04 
15 Heat shock protein Hsp 2  gi|39850111| 5.16 20425 4 123 34 -5.8 1.40E-02 
16 Myosin light chain, MLC3  gi|33563264| 5.03 22523 15 404 77 -5.2 6.00E-03 
17 Myosin light chain MLC2f, 
phosphorylatable, fast 
muscle gi|7949078| 4.82 19059 10 182 47 -4.8 8.28E-04 
18 Glyceraldehyde-3-
phosphate dehydrogenase gi|55153885| 7.59 36099 9 320 34 -4.5 4.00E-03 
19 F-actin-capping protein, 
subunit beta isoform a gi|83649737| 5.47 31616 8 142 27 -4.3 2.00E-03 
20 Myosin light chain, MLC2 gi|199985| 4.71 18870 17 235 84 -4.2 2.00E-03 
21 Triosephosphate isomerase gi|54855| 6.9 27027 2 62 10 -4.1 1.49E-04 
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22 Protein disulfide isomerase gi|129729| 4.79 57514 11 165 26 -3.2 5.00E-03 
23 Pyruvate kinase gi|31981562| 7.18 58388 18 936 39 -2.7 8.00E-03 
24 Myosin light chain MLC2f, 
phosphorylatable, fast 
muscle gi|7949078| 4.82 19059 14 236 75 -2.7 1.00E-02 
25 Pyruvate kinase gi|1405933| 7.18 58458 15 787 32 -2.6 6.00E-03 
26 Sepiapterin reductase gi|2498952| 5.58 28213 5 176 24 -2.3 4.00E-03 
27 Dihydrolipoamide S-
acetyltransferase gi|16580128| 5.71 59395 18 390 48 1.5 1.00E-02 
28 Myosin light chain MLC2f, 
fast muscle gi|7949078| 4.82 19059 12 574 77 2.4 3.00E-03 
29 UTP-glucose-1-phosphate 
uridylyltransferase gi|21314832| 7.18 57118 23 837 54 2.7 6.00E-03 
30 Tubulin, beta-3 chain gi|12963615| 4.82 50850 11 238 31 2.9 4.00E-03 
31 14-3-3 Protein gamma gi|3065929| 4.8 28519 8 231 40 3.1 1.30E-02 
32 Malate dehydrogenase, 
cytosolic gi|387129| 6.16 36628 15 245 50 3.4 1.84E-05 
33 Albumin gi|899334| 7.82 8825 2 37 30 4.6 3.30E-04 
34 Heat shock protein Hsp90-
beta  gi|40556608| 4.97 83577 11 188 16 5.2 5.00E-03 
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35 NADH dehydrogenase 
(ubiquinone) Fe-S protein 2, 
mitochondrial gi|20071222| 6.4 30361 6 211 28 5.5 5.61E-04 
36 Actin, alpha gi|4501881| 5.23 42372 17 209  5.6 1.20E-02 
37 Actin, alpha gi|4501883| 5.23 42388 7 110 19 5.7 1.30E-02 
38 Troponin T, TnT fast gi|2340068| 6.18 30297 3 141 14 6.5 6.00E-03 
39  Cofilin-2  gi|6671746| 7.66 18814 6 207 39 9.3 1.40E-02 
40 Actg2 protein gi|29437296| 5.32 22615 8 91 58 16.0 6.00E-03 
41 Succinate dehydrogenase gi|15030102| 7.11 73382 17 306 30 16.6 8.56E-04 
42  Phosphoglucomutase 2 gi|33416468| 6.02 63705 25 384 53 17.8 2.00E-03 
 
*NCBInr Database, release 20100212 
** The mascot score has a 95% confidence level if >49. 
*** Myotonic versus normal muscle tissue 
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4.2.3 Differential protein expression pattern in myotonic animal model ADR. 
Large-scale and high-resolution 2D gel electrophoresis lead to the identification of 51 muscle-
associated protein spots with a considerable change in concentration levels in the ADR mouse 
model of severe myotonia. A representative master gel with electrophoretically separated 
gastrocnemius muscle proteins is shown for the pH 4-7 and pH 6-11 range in Figure 4.4 A 
and B respectively. Muscle proteins with a myotonia-related alteration in abundance ranged in 
molecular mass from apparent 19 kDa (myosin light chain) to 98 kDa (glycogen 
phosphorylase) and covered a pI-range from approximately 4.8 (protein disulfide isomerase) 
to 9.4 (troponin). The results of the mass spectrometric identification of the 51 protein species 
are summarized in Table 4.2, which combines data from both pH 4-7 and pH 6-11 gels. The 
majority of identified proteins were shown to be constituents of the contractile apparatus, 
major metabolic pathways, the cellular stress response and various cellular signaling 
mechanisms. A reduced concentration was found for 37 muscle proteins and 13 proteins were 
shown to be increased in their density. The muscle protein species with the highest fold 
decrease was identified as the phosphorylatable fast MLC2f isoform of myosin light chain. In 
addition to the contractile protein MLC2f (spots 1, 12, 14-17, 20), triosephosphate isomerase 
(spots 2, 3), 40 kDa protein (spot 4), aminoacylase (spots 5, 13), fast troponin TnI-2 (spots 6, 
19), alpha-3 chain of tropomyosin (spots 7, 9), alpha and beta subunits of actin (spots 8, 18, 
22), troponin TnT (spots 10, 23, 26, 27), beta subunit of trifunctional enzyme (spot 11), 
otubain (spot 21), aldolase (spot 24), glycogen phosphorylase (spot 25), myosin-binding 
protein H (spot 28), four-and-a-half-LIM- domains-1 protein (spot 29), kappa-B motif-
binding proteins (spot 30), growth factor receptor bound protein 2 (spot 31), isocitrate 
dehydrogenase (spot 32), prosome (spot 33), carbonic anhydrase (spot 34), haloacid 
dehalogenase-like hydrolase (spot 35), myosin light chain isoform MLC3 (spot 36) and F-
actin capping protein (spot 37) were found to be decreased in myotonic ADR muscle. In 
contrast, the muscle protein species with the highest fold increase was identified as the 
enzyme protein disulfide isomerase (spot 51). Other increased muscle proteins were 
represented by serpin (spot 50), heat shock protein Hsp70 (spot 49), alpha subunit of 
trifunctional enzyme (spot 48), mitochondrial ATP synthase (spot 47), alpha action (spots 44 
and 46), slow MLC1s isoform of myosin light chain (spot 45), albumin (spot 43), cytochrome 
b-c1 complex (spots 38 and 42), dihydrolipoamide S-acetyltransferase (spot 41), troponin 
TnI-2f (spot 40) and ATP- specific succinyl-CoA synthetase (spot 39).  
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Figure 4.4 2-D Master gel of the ADR myotonic muscle proteome. 
Shown is a 2-D master gel of the ADR gastrocnemius muscle proteme separated in the pI 
ranges pH4-7 (A) and pH6-11 (B). Proteins with altered abundance that have been identified 
by LC/MS are numbered 1-51 and are shown in table 4.2. A total of 38 proteins were 
identified with changed abundance on the pH 4-7 (A) range and 13 protein changes were 
identified in the pH 6-11 (B) range. 
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Table 4.2 List of identified protein species that exhibit a change in abundance in ADR gastrocnemius muscle versus Normal gastrocnemius 
musce. 
 
Spot 
no. 
Name of Identified protein Accession no.
* 
pI Molecular 
mass (kDa) 
Peptides 
matched 
Mascot 
score
**
  
Coverage 
(%) 
Fold 
change
*** 
Anova 
1  Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|7949078| 4.82 19059 11 206 56 -23 2.42E-06 
2 Triosephosphate isomerase gi|2851390| 6.9 27044 12 310 64 -14.0 8.00E-03 
3 Triosephosphate isomerase gi|1864018| 5.62 22724 9 165 66 -14.0 4.39E-04 
4 40 kDa Protein gi|226005| 4.8 32848 5 119 25 -14.0 7.81E-05 
5  Aminoacylase 1  gi|13384746| 5.81 45998 10 121 29 -14.0 3.00E-03 
6 Troponin I, fast TnI-2  gi|6678391| 8.65 21518 4 236 17 -14.0 1.36E-05 
7 Tropomyosin, alpha-3 chain gi|20178336| 4.68 32901 18 176 60 -13.0 9.65E-04 
8 Actin, beta-like 2 gi|30425250|  5.3 42325 5 55 14 -13.0 3.24E-04 
9 Tropomyosin, alpha-3 chain gi|20178336| 4.68 32901 13 103 29 -13.0 4.00E-03 
10 Troponin T gi|2340048| 9.35 28318 13 500 43 -11.0 3.34E-04 
11 Trifunctional enzyme, subunit 
beta gi|21704100| 9.43 51353 12 556 24 -10.0 4.00E-03 
12  Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|7949078| 4.82 19059 11 174 61 -9.5 6.61E-04 
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13 Aminoacylase 1 gi|13384746| 5.81 45998 12 134 37 -8.9 2.00E-03 
14 Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|29789016| 4.98 20697 12 214 63 -8.3 1.00E-03 
15 Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|7949078| 4.82 19059 11 151 56 -8.3 3.00E-03 
16 Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|7949078| 4.82 19059 12 221 68 -7.2 2.54E-04 
17 Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|7949078| 4.82 19059 12 182 69 -7.1 1.50E-04 
18 Actin, alpha gi|49864| 5.45 38020 9 107 34 -7.1 3.00E-03 
19 Troponin I, fast TnI-2 gi|123242975| 8.74 15725 4 134 22 -7.0 1.30E-02 
20 Myosin light chain MLC2f, 
phosphorylatable, fast muscle gi|7949078| 4.82 19059 13 188 60 -7.0 9.66E-04 
21 Otubain 1 (OTU domain, 
ubiquitin aldehyde binding1) gi|19527388| 4.85 31482 7 186 29 -6.5 1.40E-02 
22 Actin, alpha gi|49868| 5.78 39451 12 106 34 -6.4 1.77E-04 
23 Troponin TnT gi|3449358| 6.34 29992 2 64 10 -5.9 5.00E-03 
24 Aldolase A gi|151180645| 6.61 45895 12 556 31 -5.9 1.50E-02 
25 Glycogen phosphorylase gi|6755256| 6.65 97689 26 970 34 -5.6 1.00E-02 
26 Troponin TnT gi|2340048| 9.35 28318 13 499 38 -5.5 1.00E-03 
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27 Troponin TnT  gi|2340050| 9.36 28320 6 227 18 -5.2 5.00E-03 
28 Myosin-binding protein H   gi|56676318| 5.75 53073 10 150 34 -5.1 2.00E-03 
29 Four and a half LIM domains 1 gi|123122184| 8.83 35056 3 70 10 -4.4 6.00E-03 
30  Kappa-B motif-binding 
phosphoprotein gi|1083569| 5.19 51300 10 132 26 -4.3 9.00E-03 
31 Growth factor receptor bound 
protein 2  gi|123228035| 6.31 23689 3 35 14 -3.8 5.00E-03 
32 Isocitrate dehydrogenase 3 gi|148693873| 6.11 40988 13 318 42 -3.8 1.20E-02 
33 Proteasome beta 4 subunit 
(prosome, macropain) gi|14198355| 5.47 29229 6 161 30 -3.7 4.00E-03 
34 Carbonic anhydrase CA3 gi|31982861| 6.89 29638 11 446 46 -3.1 1.40E-02 
35 Haloacid dehalogenase-like 
hydrolase domain-containing 
protein 2  isoform 1  gi|21313310| 5.7 28886 6 143 30 -3.0 1.00E-03 
36  Myosin light chain, MLC3 gi|33563264| 5.03 22523 6 127 39 -2.9 1.00E-03 
37 F-actin-capping protein, 
subunit beta isoform a gi|83649737| 5.47 31616 8 82 26 -2.8 8.00E-03 
38 Cytochrome b-c1 complex, 
subunit 1, mitochondrial gi|14548301| 5.75 53431 14 344 35 2.4 7.00E-03 
39 ATP-specific succinyl-CoA gi|3766201| 5.65 46563 21 273 46 2.4 3.00E-03 
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*NCBInr Database, release 20100212 
** The mascot score has a 95% confidence level if >49. 
*** Myotonic versus normal muscle tissue 
synthetase, beta subunit 
40 Troponin I, TnI-2f gi|148686202| 9.15 20957 6 314 24 2.8 8.00E-03 
41 Dihydrolipoamide S-
acetyltransferase gi|16580128| 5.71 59395 11 157 25 2.8 1.30E-02 
42 Cytochrome b-c1 complex, 
subunit 1 gi|14548301| 5.75 53431 8 136 20 2.9 2.00E-03 
43 Albumin gi|899334|  7.82 8825 4 66 64 3.5 2.00E-03 
44 Actin, alpha gi|33563240| 5.23 42372 13 141 50 3.5 4.18E-06 
45 Myosin light chain MLC1s, 
slow muscle gi|26986555| 5.41 22851 17 247 77 4.0 1.00E-02 
46 Actin, alpha gi|49864| 5.45 38020 9 152 36 4.7 3.00E-03 
47 ATP synthase, mitochondrial gi|20070412|  10 23407 9 374 53 5.1 3.00E-03 
48 Trifunctional enzyme, subunit 
alpha,mitochondrial gi|33859811| 9.24 82617 12 596 19 5.3 9.00E-03 
49 Heat shock protein Hsp70 gi|14917005|  5.91 73773 23 476 47 6.4 3.37E-06 
50 Serpin, B6 isoform gi|6678097| 5.53 42919 15 279 47 6.5 1.00E-03 
51 Protein disulfide isomerase gi|129729| 4.79 57514 12 142 25 13.6 6.00E-03 
  79 
4.2.4 Immunoblot analysis of potential biomarkers of myotonia in animal models MTO and 
ADR 
In order to verify key findings from our proteomic data of myotonic muscle four proteins with 
changed abundance were investigated by immunoblotting. Shown in Figure 4.10 anibodies 
directed against alpha dystroglycan in MTO and ADR muscle versus control muscle showed 
no significant differences and shows all lanes were equally loaded. As illustrated in Figure 4.5 
slow MLC2 isoform and MLC phosphorylatable were greatly reduced in MTO and ADR 
muscle tissue. The statistical significant differences Figure 4.5 (E,F,G and H) correlated well 
with our proteomic data listed in Table 4.1 and 4.2. Thus there is a reduced abundance of 
these contractile elements in severely myotonic muscle. The immunoblotting of tropomyosin 
shown in Figure 4.6 (A ,B) confirms a reduction in myotonic muscle. Similarly in Figure 4.6 
(C,D) shows a decrease in the abundance of the glycolytic enzyme triosephosphate isomerase. 
This reduction was also seen in the MTO*5J model with the more severe myotonic muscle 
ADR and MTO showing a greater reduction. As with our MTO*5J model immunoblotting of 
fiber-specific markers was carried out on both MTO and ADR muscle tissue as shown in 
Figure 4.7 and Figure 4.8. The decreased abundance of fast isoforms of MHC and increase in 
slow isoforms of MHC shown in Figure 4.7. Similarly the increased abundance of the slow 
isoform SERCA2 Figure 4.8 correlates with previously published work suggesting a 
glycolytic-to-oxidative transformation process. 
Figure 4.9 (C) and (D) shows a drastic reduction of parvalbumin in MTO and ADR 
gastrocnemius muscle respectively. This agrees with previously published work carried out by 
Jockusch and co workers (1988). An increase in myoglobin is also shown in Figure 4.9 (A) 
and (B) for MTO and ADR respectively. 
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Figure 4.5 1-D immunoblot analysis of MLC2 and MLC-phospho 20 in myotonic muscle 
Shown is the immuno-decorated nitrocellulose bands. Antibodies were directed against 
MLC2 in MTO muscle (A) and ADR muscle (B), and against MLC-phospho 20 in MTO 
muscle (C) and ADR muscle (D). The comparative immunoblotting with MTO muscle  and 
ADR muscle versus normal was statistically evaluated using unpaired Student’s t-test 
(n=4;*p<0.05,**p<0.01,***p,0.001) and is graphically shown in panels (E) and (F) for MLC2 
and (G) and (H) for MLC-phospho 20. 
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Figure 4.6 1-D immunoblot analysis of Tropomyosin and triosephosphate isomerase in 
myotonic muscle 
Shown is the immuno-decorated nitrocellulose bands. Antibodies were directed against 
tropomyosin in MTO muscle (A) and ADR muscle (B), and against triosephosphate 
isomerase in MTO muscle (E) and ADR muscle (F). The comparative immunoblotting with 
MTO muscle  and ADR muscle versus normal was statistically evaluated using unpaired 
Student’s t-test (n=4;*p<0.05,**p<0.01,***p,0.001) and is graphically shown in panels (C) 
and (D) for tropomyosin and (G) and (H) for triosephosphate isomerase. 
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Figure 4.7 1-D immunoblot analysis of MHC fast and MHC slow in both MTO myotonic 
muscle and ADR myotonic muscle 
Shown is the immuno-decoration of nitrocellulose bands. Antibodies were directed against 
MHC fast in MTO muscle (A) and in ADR muscle (B), MHC slow in MTO muscle (C) and 
ADR muscle (D). Comparative immunoblotting of myotonic muscle versus normal muscle 
was statistically evaluated using an unpaired Student’s t-test (n=4,*p<0.05,**p<0.01) and is 
grapically shown in panels (E) and (F) for MHC fast MTO and ADR respectively, panels (G) 
and (H) for MHC slow MTO and ADR respectively. 
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Figure 4.8 1-D immunoblot analysis of SERCA 1 and SERCA 2 in both MTO myotonic 
muscle and ADR myotonic muscle 
Shown is the immuno-decoration of nitrocellulose bands. Antibodies were directed against 
SERCA 1 in MTO muscle (A) and in ADR muscle (B), SERCA 2 in MTO muscle (C) and 
ADR muscle (D). Comparative immunoblotting of myotonic muscle versus normal muscle 
was statistically evaluated using an unpaired Student’s t-test (n=4,*p<0.05,**p<0.01) and is 
grapically shown in panels (E) and (F) for SERCA 1 MTO and ADR respectively, panels (G) 
and (H) for SERCA 2 MTO and ADR respectively. 
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Figure 4.9 1-D Immunoblot analysis of myoglobin and parvalbumin in myotonic muscle 
MTO and ADR 
Shown is the immuno-decorated nitrocellulose bands of 1-D gels from MTO and ADR 
muscle tissue. Antibodies directed against myoglobin in MTO tissue (A) and ADR tissue (B) 
and parvalbumin in MTO tissue (G) and ADR tissue (H). Comparative immunoblotting with 
MTO and ADR tissue versus normal tissue was statistically evaluated using an unpaired 
Student’s t-test (n=4, p<0.05,**p<0.01) shown in panels for myoglobin (E) and (F) for MTO 
and ADR respectively and parvalbumin (G) and (H) for MTO and ADR respectively. 
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Figure 4.10 1-D immunoblot analysis of alpha dystroglycan in myotonic muscle 
Shown is the immuno-decorated nitrocellulose bands. Antibodies were directed against alpha 
dystroglycan in MTO (B) and ADR muscle (D). Comparative immunoblotting of myotonic 
muscle versus control muscle was statistically evaluated using an unpaired Student’s t-test 
(n=4) and is graphically shown in panels (A) and (C) for MTO and ADR respectively.  
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4.3 Discussion 
Skeletal muscles from the ADR and MTO phenotype appear to be associated with 
considerable myotonia-related changes in proteins involved in the excitation-contraction-
relaxation cycle, energy metabolism, ion handling, cellular stress response and cellular 
signaling.  An interesting feature in both animal models was the drastic decrease in almost all 
subspecies of the phosphorylatable fast MLC2f isoform of the myosin light chain that agrees 
with previous studies of the ADR mouse (Stuhlfauth et al. 1984, Jockusch, et al.1988, Kluxen 
et al. 1988).   
 
4.3.1 Contractile Apparatus 
Previous proteomic studies have shown that isoform changes in myosin light chains represent 
reliable markers of muscle transformation (Ohlendieck 2010). Chronic low-frequency 
stimulation of fast rabbit muscle triggers a significant decrease in various MLCf molecules 
and an increase in slower counterparts (Donoghue et al. 2007). A drastic increase of slow 
myosin light chain MLC2s was observed in aging rat skeletal muscle, which is indicative of 
an increased slow fiber population in sarcopenia of old age (Gannon et al. 2009). The reduced 
density of MLC2 isoforms was seen in both MTO and ADR muscle preparations. In MTO 
muscle MLC2 phosphorylatable (spot 1,12,15,16,17,20, Table 4.1) was found to have 
decreased abundances ranging from a 23fold decrease to 7.0 fold. Similarly in ADR muscle 
preparations MLC2 phosphorylatable (spot 1,7,10,17,28, Table 4.2) was found to have 
decreased abundances ranging from 18.7 fold to 4.8 fold.  A decrease was also seen in MLC2 
in ADR muscle (spot 6,8,14,20,24, Table 4.2) ranging from 9.8-fold decrease to 2.7 fold 
decrease. A similar decrease was seen in MLC3 in ADR and also MTO muscle. MLC3 (spot 
14,36, Table 4.1) had decreased abundances of 8.3 and 2.9 respectively in MTO muscle. 
MLC3 (spot 16, Table 4.2) was found to have a 5.2 fold decrease in ADR muscle. The 
reduced density of MLC isoforms in ADR and MTO muscle preparations strongly suggests a 
partial fast-to-slow transition process in myotonia.  This transition is further suggested by the 
immunoblotting of MHC fast and slow isoforms in ADR and MTO muscle preparations 
shown in Figure 4.7. In addition, this finding confirms the idea that enhanced neuromuscular 
activity regulates the abundance of this contractile protein (Jockusch et al.1988).  
 An 8.8 fold decrease in creatine kinase (spot 9, Table 4.1) was seen in MTO muscle 
preparations. Creatine kinase catalyses the reversible conversion of creatine + MgATP to 
creatine phosphate + Mg ADP, this reaction can replenish ATP from pools of creatine 
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phosphate (Ennor et al. 1954).  Myosin ATPase preferentially uses ATP supplied by creatine 
kinase, therefore production of ATP by creatine kinase potentially plays an important role in 
skeletal muscle contraction (Bessman et al. 1980). The decrease in creatine kinase could have 
an effect on muscle contraction or could be a consequence of a change in fiber population to a 
slower oxidative metabolism, as slow type fibers have less creatine kinase (Wallimann et al. 
1984).  
 Both MTO and ADR muscle showed altered abundances of elements of the troponin 
complex. Both troponin I (spot 6,19,40, Table 4.2) and troponin T (spot 10,26,27,23, Table 
4.2) had reduced densities in ADR muscle preparations. MTO muscle preparations had a 10.3 
fold decrease in troponin I (spot 5, Table 4.1) but a 6.5 fold increase in troponin T (spot 38, 
Table 4.1). This conflicting result of troponin T may be an anomaly or an artifact from the 
lysis process. Tropomyosin the actin binding protein that mediates Ca
2+
 regulation of 
actomyosin contraction (Nagai et al. 2001), was decreased in both ADR (spot 7,9, Table 4.2) 
and MTO (spot 13, Table 4.1). The decrease in the structural protein myosin binding protein 
H in both ADR (spot 28, Table 4.2) and MTO (spot 4, Table 4.1) is also seen. This protein is 
involved in the interaction with the thick filaments in the A band of the sarcomere. A decrease 
in actin-capping protein was seen in both ADR (spot 37, Table 4.2) and MTO (spot 19, Table 
4.1). This protein regulates the growth of the actin filament by capping the barbed end of 
growing actin filaments. These findings correlate with previous studies on the contractile 
properties of myotonic muscle (VanLunteren et al. 2006). VanLunteren and co-workers 
carried out analysis on diaphragm muscle from ADR mice. This study found CLC-1 deficient 
diaphragm had impaired isometric force generation compared to wild type. Similarly in MTO 
mice Entrikin and colleagues (1987) found reduced peak isometric tension in portion to the 
reduction in muscle weight. Reductions in contractile proteins could contribute to a decrease 
in force generation during muscle contraction in gastrocnemius muscle in both ADR and 
MTO muscle. 
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4.3.2 Muscle transformation  
The shift of myosin isoforms as a result of myotonia can be seen in Figure 4.7. The decrease 
in MHCf in myotonic muscle is coupled with an increase in the expression of the MHCs 
subunit. A similar differential isoform expression pattern of the Ca
2+
 pump SERCA can be 
seen in Figure 4.8. Immunodecoration of SERCA isoforms in myotonic muscle show a 
decrease in the fast SERCA1 isoforms and an increase in the slow SERCA2 isoform. These 
results correlate well with the idea of muscle transformation from fast-to-slow in myotonic 
muscle. 
   
 4.3.3 Energy metabolism 
This proteomic study of myotonic muscle has shown changes in many metabolic enzymes. 
Albumin is a major plasma protein that is responsible for the extracellular transport of fatty 
acids, amino-acid storage and osmotic pressure maintenance (Ellmerer et al. 2000). The 
upregulation of albumin in both ADR (spot 43, Table4.2) and MTO (spot 33, Table4.1) 
muscle preparations may be due to increased expression or the possible higher capacity of 
albumin storage by the transformed fibers. The optimum utilization and transportation of free 
fatty acids seem to be important factors in the aerobic metabolic potential of slower 
contracting fibers (Kaufmann et al. 1989). In the case of the trifunctional enzyme its beta 
subunit (spot 11, Table 4.2) was reduced and its alpha subunit increased (spot 48, Table 4.2) 
in ADR muscle preparations. Similar increases in oxidative phosphorylation enzymes were 
seen in both ADR and MTO muscle preparations. They can be seen in Table 4.2 and include 
cytochrome C in ADR muscle (spot 38), ATP succinyl-CoA (spot 39) and ATP synthase (spot 
47). Increases in MTO muscle preparations of oxidative phosphorylation enzymes are shown 
in Table 4.1 and included NADH dehydrogenase (spot 35) and SHDA (spot 41) both are 
enzymes functioning in oxidative phosphorylation in the mitochondrion. The above changes 
in myotonic muscle suggest an increase in mitochondrial enzyme activity and a shift to more 
oxidative metabolic pathway indicative of slower twitching fiber population.     
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4.3.4 Stress response 
The expression of heat shock proteins Hsp70 in ADR (spot 49, Table 4.2) increased 6.4 fold 
and Hsp90 in MTO (spot 34) by 5.2 fold. Increases in heat shock proteins indicate the 
response of myotonic muscle to cellular stress. Hsp90 and Hsp 70 act as chaperones during 
protein unfolding and denaturation by nonphysiological events. Harris and co-workers (2008) 
found an increase in Hsp90 in soleus muscle after exercise. Similarly Neufer and colleagues 
(1996) found CLFS of rabbit tibialis anterior resulted in significantly elevated levels of 
Hsp70. It is also interesting to note that Neufer and co-workers (1996) saw an increase 
expression of Hsp70 in muscles rich in type 1 fibers. This increase was also accompanied by 
an increase in Hsp60 in type 1 fibers which is interesting as Hsp60 was found to be increased 
in MTO*5j muscle preparations. Changes in expression of stress proteins could aid in the 
remolding process evoked by the sustained contractile activity in myotonic muscle.  Hsp 2 
(spot 15) and Hsp7 (spot 3) shown in Table 4.1 were both decreased in MTO muscle. 
Similarly, in ADR 40kDa protein (Hsp40) (spot 4, Table 4.2) was increased in ADR muscle. 
This increase in heat shock proteins indicates that fiber modifications probably depend 
heavily on the chaperone function of heat shock proteins. 
 
4.3.5 Other proteins 
In addition to the above-discussed alterations in common fiber type-specific markers, many 
other interesting changes in distinct protein species occurred in the myotonic animal models. 
The actin binding protein cofilin-2 (spot 39, Table 4.1) was found to be increased 9.3 fold in 
MTO muscle preparations. Cofilin-2 plays an important role in actin filament dynamics (Ono 
et al. 1994). This muscle specific isoform is thought to be important for growth of myofibrils 
in developing and regenerating muscle cells (Thirion et al. 2001, Nakashima et al. 2005). 
Donoghue and colleagues (2007) investigated muscle adaptation process in response to 
enhanced neuromuscular activity and found a similar increase of cofilin-2 in stimulated 
tibialis anterior muscle. The upregulation in cofilin-2 in myotonic transforming fibers could 
be in response to remodeling of contractile apparatus towards slower twitch properties.  
 DJ-1 (spot 2, Table 4.1) is decreased drastically in MTO muscle. DJ-1 migrates to 
mitochondrion during oxidative stress due to actions of chaperones. It is an atypical 
peroxiredon that protects cells from cell death due to oxidative stress (Chen et al. 2010). An 
impaired stress response could lead to a detrimental aggregation of misfolded proteins and 
oxidative damage resulting in dysfunction and muscle weakness seen in myotonic muscle. 
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 Four and a half LIM domain 1 (FHL1) (spot 29, Table 4.2) is characterized by the presence 
of four and a half highly conserved LIM domains. The LIM domain is a protein-interaction 
motif and is involved in linking proteins with both actin cytoskeleton and transcriptional 
machinery (Shathasivam et al. 2010). Today 27 mutations of the gene encoding FHL1 have 
been recorded and result in at least six different X-linked myopathies (Shathasivam et al. 
2010) indicating FHL1 protein is required for normal muscle function.   
  The reduced density of carbonic anhydrase isoform CA3 (spot 34, Table 4.2) in ADR muscle 
could be interpreted as a potential impairment of the CO2-removal mechanism in myotonia. 
Carbonic anhydrase converts CO2 into carbonic acid (Geers et al. 2000), therefore its lower 
expression levels may trigger a reduced availability of this essential hydration reaction that 
may result in harmful levels of CO2 in myotonic fibers. 
 The enzyme disulfide isomerase was found to be increased in ADR muscle, but decreased in 
MTO. This thiol-disulfide oxidoreductase of the sarcoplasmic reticulum catalyzes the 
exchange of a disulfide bond with substrates thereby facilitating correct protein folding. The 
alternate changes in density in ADR and MTO muscle could be potentially used as a 
differentiating marker of these two different myotonic phenotypes. 
 
4.3.6 Overview of alterations in ADR vs. MTO vs. MTO*5J 
The graphical presentation of Figure 4.11 and Table 4.3 gives an overview of major changes 
in distinct classes of protein in hyperexcitable muscle tissues as revealed by mass-
spectrometry-based proteomics. A striking feature in all animal models was the drastic 
decreased in a number of subspecies of phosphorylatable fast MLC2f isoform of myosin light 
chain. Our table shows this reduction along with the metabolic trend of a glycolytic-to-
oxidative transformation as well as an increased cellular stress response in hyperexcitable 
muscles. The direct comparison of the 3 mutants also shows that the concentration changes in 
proteins are more pronounced in the serve MTO and ADR phentotypes as compared to the 
milder MTO*5J phenotype. 
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Table 4.3 List of protein species that exhibit a change in abundance in ADR, MTO and MTO*5J muscle. 
 
Name of Identified Protein ADR Fold Change MTO Fold Change MTO*5J Fold Change 
Myosin Light Chain MLC2f, 
phosphorylatable, fast muscle 
-23, -9.5, -8.3, -8.3, -7.2, -7.1, -7.0 -18.7, -9.8, -8.0, -6.1, -4.8, -2.7,  -3.6,  
T complex protein 1 -14.0 -10.3 -3.6 
Triosephosphate Isomerase -14.8, -3.8 -4.1 3.7 
Troponin T fast skeletal muscle -5.2, -5.5 8.5, 6.5 6.0 
NADH dehydrogenase  5.5 2.9 
ATP synthase, mitochondrial 5.1  3.0 
Albumin 3.5 4.6  
F-actin capping protein -2.8 -4.3  
Hsp 27   2.9 
Hsp 90  5.2  
Hsp 70 6.4   
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Figure 4.11 Overview of changes in myotonic muscle 
A single nucleotide replacement or other event at the DNA level in the Clc1 gene is sufficient 
to cause loss of function of the muscular chloride channel CIC-1. In mammalian muscle, CIC-
1 is expressed in the sarcolemma of mature muscle, and is required for normal muscle 
function. Loss of function CIC-1 leads to hyperexcitability of the muscle fiber. Unscheduled 
bursts of action potentials cause a burst of intracellular Ca
2+ 
activities e.g. Ca
2+
-dependent 
signaling pathways. In myotonic muscle this results in a change in transcription patterns 
leading to a fiber shift from fast glycolytic (Type IIB) to fast oxidative (Type IIA) and even to 
slow (Type I).  This fiber type shift is also mirrored at the metabolic level by increases in 
oxidative enzymes and reduction in glycolytic enzymes. Presumably due to cramps and 
imbalance of gene expression, there is a considerable cellular stress response in myotonic 
muscle fibers.
  93 
4.5 Conclusion 
Myotonia appears to trigger considerable changes in many elements of the contractile 
apparatus, cellular processes and muscle energy metabolism. Our proteomic finding has 
shown that a single mutation in a muscle-specific gene that triggers hyperexcitability of the 
sarcolemma has severe downstream effects on the expression levels of a very large number of 
genes in contractile tissues. Comparing results from this study with results from chapter 3 
indicates that the milder disease progression in the MTO*5J mouse is associated with less 
pronounced downstream effects on the global muscle proteome complement. 
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5. DIGE analysis of skeletal muscle affected by motor neuron degeneration 
 
5.1 Introduction 
Motor neuron diseases are a heterogeneous group of fatal neurological diseases (Wood-Allum 
and Shaw 2010). They include spinal muscular atrophy, spinal bulbar muscular atrophy and 
amyotrophic lateral sclerosis (ALS). Spinal muscular atrophy is an autosomal recessive 
disorder caused by a mutation in the survival motor neuron SMN1 gene and is characterized 
by low motor neuron degeneration. Spinal bulbar muscular atrophy is triggered by expansion 
of a polyglutamine tract in androgen receptor gene and is characterized by slowly progressive 
motor neuron degeneration with adult-onset. ALS can be sporadic or caused by a genetic 
mutation. It is the most progressive and frequent form of adult-onset motor neuron disease 
(Wijesekera and Leigh 2009). ALS is shown to be due to genetic abnormalities in the Cu/Zn 
superoxide dismutase 1 gene and also the TDP-43 encoding TARDBP gene (Wijesekera and 
Leigh 2009). 
The degeneration of motor neurons leads to weakness of contractile limb, bulbar and 
respiratory tract. Patients with ALS experience highly progressive paralysis that is usually 
fatal due to respiratory failure within 2-3 years after bulbar onset or 3-5years after limb onset 
cases. Today, only one drug has regulatory approval for the treatment of ALS and is called 
glutamate antagonist riluzole. It prolongs survival time in the treatment of ALS but only by 3-
4 months (Miller et al. 2007). This is due to very poor prognosis of patients with ALS.  In 
order to improve prognosis and treatment of ALS it is important that detailed biomedical 
investigations into its pathogenesis is carried out along with searches for new therapeutic 
targets. 
The wobbler mouse (allele wr) is a recessive mutation mapped to chromosome 11 on the 
mouse genome and is caused by a mutation in the ubiquitously expressed gene Vps54 
(Kaupmann et al. 1992).  The gene Vsp54 encodes the vesicular protein sorting factor vps54, 
which is a component of the GARP complex. The GARP complex is involved in retrograde 
vesicle transport to the golgi apparatus and plays a crucial role in intracellular transport. 
Studies where Vsp54 expression was knocked out in mice resulted in embryonic lethality 
(Schmitt-John et al.2005). The wobbler mouse has rapid disease progression and is an 
established animal model of human motor neuron disease. It is characterized by cellular 
abnormalities including muscular atrophy and is a highly valuable model for many aspects of 
motor degeneration including neuroinflammatory processes. 
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In this study we have used here fluorescence difference in-gel electrophoresis to analyze 
global changes in the skeletal muscle proteome from WR versus normal mice.  
 
5.1.2 DIGE 
DIGE is a 2-D gel elctrophoresis technique that uses ester cyanine dyes to label proteins 
before 2-D gel electrophoresis. Today there are three cyanine dyes available comerically; Cy3 
(propyl-Cy3 N-hydroxysuccinimide (NHS) ester cyanine), Cy5 (methyl-Cy5 NHS ester 
cyanine) and Cy2. In this study we have used Cy3 and Cy5. The ester cyanine dyes form a 
covalent bond with the primary amine of the amino acid lysine and results in an amide linkage 
between the dye and the protein. Both Cy3 and Cy5 have the same molecular mass and 
reactive group but different excitation emission spectra (Unlu et al. 1997). The advantage of 
using these dyes is that they are charge matched to lysine and so ensure negliable shift in pI 
during the first dimension. They can also detect a minimum of 0.25 ng of protein and can 
linearly detect protein over greater than 10,000 fold change (Tonge et al. 2001). Another 
feature of DIGE is the inclusion of an internal pooled standard. The pooled standard is the 
combination of  equal amounts of protein from all samples in the experiment. In this study we 
used Cy5 as our pooled standard and Cy3 for our individual samples. This means on each 
strip and then gel an internal pool standard is run along with either a diseased or control 
sample. As all test samples are labelled with the same dye any dye bias is eliminated. Also as 
unique excitation and emission spectra are required for both dyes two images are obtained per 
gel; the internal standard and control/diseased sample. Analysis using Progenesis Same Spot 
software version 3.2.3 from NonLinear Dynamics (Newcastle Upon Tyne, UK)samples are 
normalised by comparing samples to pooled standard generating a ratio of spot volume 
pool:sample. This ratio can then be compared across all gels eliminating technical variation 
between gels and also reducing the number of gels to be run in the experiment. 
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5.3 Results 
 
5.3.1 DIGE experimental design 
Proteins were separated on a 24cm strip in the pH range of pH3-10. A 50 mg protein sample 
was fluorescently labelled for each of the protein samples being studied. Normal (n=4)muscle 
extracts and WR (n=4) muscle extracts were each labelled with Cy3 DIGE Fluor dye and the 
pooled internal standard with Cy5 DIGE Fluor dye. The 2D-GE separation of fluorescently 
labelled proteins was carried out by using a total of 100 mg protein per DIGE gel. Two 
images were obtained from each gel and can be seen in Figure 5.1. Following DIGE analysis 
analytical gels were then performed to obtain protein samples for mass spectrometric analysis. 
Figure 5.2 shows a RuBPs stained analytical gel that was used for spot picking for mass 
spectrometry analysis. 
  97 
 
 
 
Figure 5.1 2-D gel elctrophoric analysis of wobbler versus control skeletal tissue 
Shown is the 2-D DIGE analysis of wobbler versus normal skeletal muscle. Shown are Cy3-
labelled gels of total muscle extracts from wobbler (WR1 to WR4) versus normal wild type 
(WT1 to WT4) mice, as well as Cy5-labelled gels containing pooled standards. DIGE images 
are shown for the pH 3-10 range. 
  98 
5.3.2 DIGE analysis of skeletal muscle 
The most prominent changes in gene expression in muscles affected by motor neuron 
degeneration are expected to reflect physiological denervation. In fact, an increase of the 
mRNA for the a-subunit of the nicotinic acetylcholine receptor, a typical sign of denervation, 
has been found in WR muscle (Sedehizade et al. 1997). Following differential fluorescent 
tagging, gel electrophoretic separation, densitometric scanning and image analysis, 24 protein 
spots were identified in WR muscle tissue that exhibit a significant change in concentration 
levels. A representative RuBPs master gel is shown for the pH 3-10 range in Figure 5.2. WR-
associated changes in the concentration of proteins included two-dimensional spots that 
covered a pI-range from approximately 4.1 (Troponin C) to 8.6 (GAPDH) and ranged in 
molecular mass from apparent 16 kDa (Cu/Zn superoxide dismutase) to 128 kDa (Myosin 
binding protein C). The findings from the mass spectrometric identification of the 24 protein 
spots with a changed abundance are presented in Table 5.1. Expression levels were reduced in 
the case of 3 protein species and increased for 21 proteins. The spot with the highest relative 
concentration was found for the glycolytic enzyme aldolase (spot 1, Table 1), followed by 
GAPDH (spot 2). Other increased proteins are represented by actin (spots 4, 9, 16, 19), 
desmin (spots 5, 7, 11), myoglobin (spots 6, 12), myozenin (spot 8), troponin C (spot 14), 
actinin (spot 15), Cu/Zn superoxide dismutase (spot 20) and fast myosin light chain 1f (spot 
21). Subtypes of creatine kinase M-type, possibly representing differently phosphorylated 
isoforms, showed differential changes in a variety of protein spots. Five spots exhibited an 
increased abundance (spots 3, 10, 13, 17, 18) and one spot a decreased concentration (spot 
22). A decrease was shown for 2 proteins spots which both represent fast myosin binding 
protein C (spots 23, 24). 
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Figure 5.2 DIGE analysis of wobbler versus control tissue 
Shown is a RuBPs-labelled master gel of crude tissue extracts from WR muscle tissue 
covering the pH 3-10 range. Protein spots with a changed concentration in WR preparations 
are marked by circles and are numbered 1 to 24. See Table 5.1 for a detailed listing of muscle-
associated protein species with a changed abundance in the WR mouse model of motor 
neuron disease. The pH-values of the first dimension gel system and molecular mass 
standards (in kDa) of the second dimension are indicated on the top and on the left of the 
panels, respectively. 
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Table5.1 Proteins with changed abundance identified by LC-MS in WR versus normal skeletal muscle. 
 
Spot 
no. 
Name of identified 
protein 
Accession no. 
* 
pI Molecular mass 
(kDa) 
Peptides 
matched 
Mascot 
score
** 
Coverage 
(%) 
Fold 
change
*** 
Anova 
1 Fructose-bisphosphate 
aldolase A gi|6671539| 8.31 39795 2 79 10 0.002 4.5 
2 Glyceraldehyde-3-
phosphate dehydrogenase  gi|149257623| 8.63 36298 6 101 24 0.002 3.5 
3 Creatine kinase M-type gi|6671762| 6.58 43250 15 447 41 0.006 3.4 
4 Actin, alpha-cardiac gi|387090| 5.23 42043 12 176 32 0.005 3.4 
5 Desmin gi|33563250| 5.21 53523 25 577 57 0.003 3.3 
6 Myoglobin gi|21359820| 7.07 17117 7 249 59 0.007 3.2 
7 Desmin  gi|33563250| 5.21 53523 27 475 60 0.004 3 
8 Myozenin-1  gi|10946924| 8.57 31438 6 159 25 0.008 3 
9 Actin, alpha-cardiac gi|387090|  5.23 42043 12 185 37 0.009 3 
10 Creatine kinase M-type  gi|6671762| 6.58 43250 7 305 20 0.011 2.8 
11 Desmin  gi|33563250 5.21 53523 21 369 49 0.008 2.6 
12 Myoglobin gi|21359820| 7.07 17117 7 274 49 0.002 2.6 
13 Creatine kinase M-type gi|6671762| 6.58 43250 5 113 14 0.008 2.3 
14 Troponin C, skeletal gi|6678371| 4.07 18156 6 308 49 0.005 2.2 
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muscle 
15 Actinin-3, alpha  gi|7304855| 5.31 103616 14 330 21 0.006 2.1 
16 Actin, alpha-cardiac gi|387090| 5.32 42048 11 89 28 0.013 1.9 
17 Creatine kinase M-type  gi|6671762| 6.58 43250 6 102 18 0.007 1.8 
18 Creatine kinase M-type gi|6671762| 6.58 43246 7 295 23 0.011 1.7 
19 Actin, alpha gi|49864| 5.45 38020 8 121 30 0.01 1.7 
20 Cu/Zn superoxide 
dismutase gi|226471| 6.03 15926 7 156 47 0.005 1.6 
21 Myosin light chain 1f gi|29789016| 4.98 20697 13 187 61 0.013 1.4 
22 Creatine kinase M-type gi|6671762| 6.58 43250 10 152 25 0.004 0.5 
23 Myosin binding protein 
C, fast  gi|20988232| 6.02 128115 14 170 15 0.003 0.4 
24 Myosin binding protein 
C, fast  gi|20988232| 6.02 128100 22 344 26 0.013 0.4 
*NCBInr Database, release 20100212 
** The mascot score has a 95% confidence level if >49. 
*** Wobbler versus normal muscle tissue 
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5.2.3 Immunoblot validation of DIGE analysis 
In order to verify key proteomic findings and to put this study in to perspective with previous 
analyses of WR muscle tissues, representative immunoblots are shown in Figure 5.3, Figure 
5.4. and Figure 5.5 . Immunoblotting shown in Figure 5.3 clearly confirmed our proteomic 
data and showed a drastically increased abundance of GAPDH and desmin in WR muscle. 
However, increased levels of Cu/Zn superoxide dismutase shown in Figure 5.4 (B, D) were 
not significant. Similarly increased levels of myoglobin Figure 5.4 (A, C) shows a slight 
increase in Wobbler skeletal muscle. Previously published work on mRNA of the cytosolic 
Ca
2+
-binding protein parvalbumin showed a drastic decrease in the wobbler (Sedehizade et al. 
1997). The immunoblot of parvalbumin versus control in wobbler skeletal tissue shown in 
Figure 5.5 also agrees with this previously published work. 
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Figure 5.3 Immunoblot analysis of muscle proteins with a differential expression pattern 
in wobbler fibers 
Shown is 1-D immuno-decorated bands and graphical presentation of statisical evaluation of 
antibody labelling, representing GAPDH (A, C), Desmin (B, D). The comparative blotting 
was statistically evalutated using an unpaired Student’s t-test (n=4, **p<0.01,*p<0.05). 
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Figure 5.4 immunoblot analysis of Myoglobin and Cu/Zn SOD in wobbler skeletal tissue 
Shown is the immuno-decorated band and graphical presentation of statistical evaluation of 
antibody directed against myoglobin (A,C) and Cu/Zn SOD (B, D). The comparative blotting 
was statistically evaluated using an unpaired Student’s t-test (n=4,*p,0.05). 
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Figure 5.5 Immunoblot analysis of Parvalbumin in wobbler skeletal tissue. 
Shown is the immuno-decorated band and graphical presentation of statistical evaluation of 
antibody directed against parvalbumin (A, B). The comparative blotting was statistically 
evaluated using an unpaired Student’s t-test (n=4, *p,0.05). 
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5.3 Discussion 
The overall objective of our proteomic profiling study of the WR skeletal muscle proteome 
was the establishment of global effects of motor neuron disease on the protein complement 
from skeletal muscle tissue. Since conventional protein staining procedures have a limited 
dynamic range, we employed fluorescence DIGE analysis for the detailed characterisation of 
global changes in the WR muscle proteome. A total of 24 protein spots were identified in WR 
muscle tissue that exhibited a significant change in concentration levels. Expression levels 
were reduced in the case of 3 protein species and increased for 21 proteins. Identified proteins 
were associated with key metabolic pathways, the contractile apparatus, intermediate 
filaments and the cellular stress response. 
 
5.3.1 Metabolism 
Muscular atrophy is a process in which protein degradation exceeds protein synthesis 
resulting in a decrease in fiber size, a drastic loss in muscle tissue mass and a decrease in 
isometric force (Staunton et al. 2011). It is observed in skeletal muscles under certain 
conditions including: microgravity, traumatic injury, following extended periods of rest or 
pathological damage to motor neurons (Kandarian et al. 2006). Previous studies have noted 
muscular atrophy results in an increase in key enzymes in the glycoltic pathway (Li et al. 
2005; Sun et al. 2006; Seo et al. 2006). Aldolase A (spot 1) converts fructose 1,6-
bisphosphate to glyceraldehyde-3-phosphate and dihydroxyacetone phosphate during 
glycolysis. Interestingly our second protein with increased abundance in WR muscle was 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which converts glyceraldehyde-3-
phosphate to 1,3 bisphosphoglycerate. This drastic increase in GAPDH was clearly confirmed 
by immunoblotting shown in Figure 5.3 (A).These results agree with previous studies of 
muscle unloading which results in muscle atrophy (Seo et al. 2006) where enzymes associated 
with anerobic metabolism showed a significant increase in expression following unloading. 
Previous work by Sedehizade and co-workers (1997) showed a decrease in the Ca
2+
-binding 
protein parvalbumin in WR muscle. Similarly in figure 5.5 immunoblotting confirmed this 
reduction in parvalbumin in WR skeletal muscle tissue.  
 Metabolic regulatory protein creatine kinase M chain is presented in multiple spots (Spot 3, 
10,13,17,18) this may be due to multiple phosphorylation isoforms. Phosphorylation is a post 
translational modification whereby phosphate groups are linked to the hydroxyl group of  
tyrosine, serine or threonine residues (Gannon et al. 2008). Therefore the representation of 
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creatine kinase  as multiple spots on the gel may be due to the addition of one or multiple 
phosphate groups to the protein affecting its location on the gel. In order to fully determine 
phosphorylated isoforms of creatine kinase a ProQ diamond stain could be used to assess 
phosphorylated proteins with changed abundance in WR skeletal tissue. Creatine kinase M 
can reversibly catalyses the transfer of phosphate between ATP and creatine phosphate. 
Similar to aldolase A creatine kinase M-type was found to be increased in muscle tissue 
subjected to unloading (Cros et al. 1999). This overexpression of creatine kinase M-type was 
seen at early days of unloading and so considered a marker for muscle disuse (Cros et al. 
1999). This drastic increase in creatine kinase M-type imply crucial alterations in creatine 
phosphate metabolism that may be related to metabolic shifts in WR muscle tissue due to 
muscle disuse due to denervation. 
 On one hand the decrease in parvalbumin which has been shown to be expressed in fast 
glycolytic muscle fibers along with an increase in oxygen transporting protein myoglobin 
(spot 6,12) shown in Figure 5.4 (A), and elvated levels of key glycolytic enzymes on the other 
indicate that the metabolic transformation in WR muscle is more complex than a 
unidirectional shift towards an extremely glycolytic phenotype.  
 
5.3.2 Contractile apparatus and intermediate filaments 
Changes in the concentration of actin (spot 4,9,16,19), troponin C(spot14), actinin (spot 15), 
myozenin-1 (spot 8), myosin light chain 1f (spot  21) and myosin binding protein c,fast (spot 
23,24) suggest atrophy-related modulations of the contractile apparatus. Skeletal muscle 
myosin is composed of two heavy chains, two essential light chains (MLC1), and two 
regulatory light chains (MLC2). Myosin light chains are responsible for force and velocity in 
muscle fibers (Sato et al. 2009). Therefore the 1.4 fold increase in MLC 1 the fast isoform is 
expected to happen as a consequence of the lowering of mechanical load with denervated 
muscle.  Myozenin-1 was first described by Takada and co-workers (2001) and was found to 
- -actinin isoforms function to 
anchor the actin containing thin filaments (Takada et al. 2001). Changes in proteins of the 
contractile apparatus may be a result of remodelling due to muscle transformation as a 
consequence of denervation. 
 Desmin (spot 5,7,11) is part of the intermediate filament family of proteins that form the 
fibrous network connecting myofibrils to each other and the plasma membrane from the 
periphery of the Z-line. Desmin null mice show disorganisation of myofibril architechture and 
  108 
mutations of the desmin gene underlie certain mutations of muscular dystrophies (Farve et al. 
2011). This indicates the importance of desmin for integrity of cytoarchitechture in skeletal 
muscle cells.  The upregulation of desmin could be possibly a compensatory stabilisation of 
the cytoskeletal network in WR muscle. Similarly increases in the essential contractile protein 
actin and its achoring proteins actinin and myozenin and the intermediate filament protein 
desmin on one hand and the decrease in the myosin binding protein C on the other, may be 
due to contractile remodelling due to fiber transformations in the WR muscle. 
  
5.3.3 Other proteins 
The upregulation of anti-oxidant marker Cu/Zn superoxide dismutase (SOD) (spot 20) 
indicates a need to counter-act cellular damge due to motor neuron degeneration in the WR 
mouse. Cu/Zn SOD destroys any reactive oxygen species that are produced by the cell. It is 
interesting that this protein would be increased in the transformed glycoltic WR muscle. 
Mutations in Cu/Zn SOD have been show in 20% of cases with autosomal dominant FALS 
and 2% of patients with SALS (Wijesekera and Leigh 2009). 
 
5.4 Conclusions 
Studying changes in the WR muscle proteome has the potential to contribute crucial 
information on disease process during denervation-induced muscular atrophy. The proteomic 
profiling of muscular atrophy associated with motor neuron disease has revealed key enzymes 
of the glycolytic pathway and increase contractile proteins, such as actin, troponin C, actinin 
and myozenin-1. The proteomic data represented supports the general idea of disuse-and 
atrophy-associated oxidative-to-glycolytic transformation process. 
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6. Mass Spectrometric identification of sarcoplasmic reticulum proteins by “on 
membrane” digestion. 
 
6.1 Introduction 
In this study we have applied a combination of subcellular fractionation, one-dimensional 
gradient-gel electrophoresis, on-membrane digestion and MS analysis to determine the 
complex composition of the sarcoplasmic reticulum (SR) from rabbit skeletal muscle. The SR 
of skeletal muscle is made of an elaborate system containing integral proteins and large 
proteins that exist in highly complex supramolecular clusters. Its central role is in the 
regulation of the excitation-contraction-relaxation cycle and Ca
2+ 
homeostasis. Major proteins 
involved in Ca
2+
-uptake,Ca
2+
-shutting, Ca
2+
-buffering and Ca
2+
-release are represented by 
SERCA-type Ca
2+
 pumps including; Ca
2+
-binding protein sarcalumenin (SAR), high capacity 
Ca
2+
 binding element calsequestrin and the ryanodine receptor release channel (Ryr). Minor 
proteins involved in the modulation of excitation-contration coupling include; mitsugumin-
29, junctophilin-1, trimeric intracellular cation-selective channel (TRIC-A), JP-45,JP-90, 
junctin, triadin, the SERCA-regulatory subunits:phospholamban and sarcolipin and the Ryr-
associated FKBP12 immunophilins. Primary and secondary defects in Ca
2+
-homeostasis 
proteins result in numerous neuromuscular disorders including; malignant hyperthermia, 
central core disease, Brody’s disease and dystrophinopathy. These peripheral and integral 
Ca
2+
-regulatory proteins of the SR are maintained as large oligomeric assemblies in muscle 
fibers which makes them difficult to identify by MS following 2-D gel electrophoresis. 
Conventional 2-D gel electrophoresis where proteins are separated in the first dimension 
based on their pI and in the second based on their molecular mass underestimates the presence 
of integral proteins, very large proteins, proteins with extreme pI values and proteins with low 
copy number. Subcellular fractionation reduces sample complexcity and so can overcome 
problems with low abundance proteins. The use of 1-D gradient gels eliminates the exclusion 
of integral proteins and high molecular mass components. In addition, normal gel-
electrophoresis-based proteomics studies use mostly in-gel digestion for generation of 
peptides to be analyzed by MS technology. However, in-gel trypsination of gel-separated 
proteins in low digestion efficiency and thus a relatively low yield of proteolyic peptides. This 
is a problem with low abundance proteins, integral proteins or high molecular mass proteins. 
In this study in order to address these problems we have used 3-12% large gradient gels for 
the electrophoretic separation of SR-associated protein complement and on membrane 
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digestion methods to identify proteins by MS. On membrane trypsination mehods have been 
applied in various biochemical studies (Aebersold et al. 1987; Luque-Garcia et al. 2008; 
Towbin et al. 1979; Lewis et al. 2010). In contrast to in-gel trypsination, proteins that are 
transferred to nitrocellulose sheets are readily accessible to proteases thus increasing digestion 
efficiency and reducing digestion time making trypsin autolysis at least partically eliminated.  
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6.2 Results 
6.2.1 Subcellular fractionation 
Crude microsomal vesicles were prepared from skeletal muscle homogenates by standard 
differential centrifugation and then the heavy SR fraction was separated from sarcolemma, 
triads junctions, light SR and mitochondrial debris by sucrose density gradient centrifugation. 
Subsequently, 3-12% gradient gel electrophoresis was employed to achieve a highly 
reproducible banding pattern of the protein complement from the SR-enriched fraction. SR 
proteins were transferred to nitrocellulose membranes and individual bands digested by on-
membrane trypsination. The unambiguous identification of SR-associated proteins was 
achieved by LC-ESI MS/MS analysis. 
 
6.2.2 SDS-PAGE fractionation 
The gel electrophoretic separation of the SR fraction resulted in a distinct protein band pattern 
shown in figure 6.1. As illustrated in the representative gradient gel of Figure 6.3. Ponceau 
Red staining revealed 35 distinct protein bands, ranging in molecular mass from 12 kDa 
(S100 Ca
2+
-binding protein) to 571 kDa (RyR1 SR Ca
2+
-release channel). Major protein 
bands were represented by creatine kinase (band 20), CSQ (bands 14 and 15), SERCA Ca
2+
-
ATPase (bands 5, 10 and 11) and the RyR1 isoform of the SR Ca
2+
-release channel (band 1). 
Despite repeated attempts to analyze their protease-generated peptide mixtures, 5 proteins 
bands, i.e. SR bands 3, 16, 19, 29 and 30, could not be identified. In contrast, the most 
intensively stained protein band of approximately 110 kDa contained 5 distinct groupings of 
MS hits (bands 10a, 10b, 11a, 11b and 11c). Band 23 could also be subdivided into 2 distinct 
MS hits (bands 23a and 23b). 
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Figure 6.1 Banding pattern of SR 1-dimensional gel. 
Shown is the reversible memcode stained distinct banding pattern of SR fraction proteins 
separated on a 3-12% gradient gel. The multiple lanes represent multiple repeats of the SR 
fraction. 
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Figure 6.2  One-dimensional master gradient gel. 
Shown is a representative Ponceau Red-stained nitrocellulose replica of the 
electrophoretically separated SR fraction, using a large 3-12% gradient gel system. SR protein 
bands were numbered 1 to 35 and identified by MS analysis (see: Table 6.1). Molecular mass 
standards (in kDa) are indicated on the left of the panel. 
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6.2.3 Identification of sarcoplasmic reticulum proteins by LC/MS 
The MS-based identification of the main protein species that represent stained bands 
following one-dimensional gradient gel electrophoresis is summarized in Table 6.1. Table 6.1 
lists identified proteins in the SR fraction from rabbit skeletal muscle as determined by a 
minimum coverage by two independent peptide sequences. The table gives an overview of the 
name of identified protein species, peptide sequences, number of matched peptides, the 
percent sequence coverage, molecular mass, isoelectric point, Mascot score and protein 
accession number. Clearly identified proteins in the SR fraction were the RyR1 isoform of the 
Ca
2+
-release channel (band 1), the SERCA-type Ca
2+
-pump (bands 4, 5, 8, 9, 10a, 10b, 11a, 
11b, 11c), the Ca
2+
-binding protein CSQ (bands 14 and 15), the 53-GP/SAR protein (band 
17), elongation factor 1-alpha (band 18), creatine kinase (band 20), aldolase (band 23a), 
protein similar to C34G6.1 (band 24), and ADP/ATP translocase 3 (band 3). Some Identified 
proteins were identified with only one matched peptide and are placed in Table 6.2
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Table 6.1. List of MS-identified proteins in the sarcoplasmic reticulum fraction from rabbit skeletal muscle. 
Band 
No. 
Name of 
identified 
protein Peptide sequence 
Peptides 
matched 
Coverage 
(%) 
Molecular 
mass 
(Da) pI 
Mascot 
score Accession No.
* 
1 
Ryanodine 
receptor RyR1 
calcium 
release channel 
LFPAVFVLPTHQNVIQFELGK 
DPVGGSVEFQ 
FVPVLK 
FAVFVNGESVEENANVVVR 
GEGGSGLLAAIEEAIR 
LVFDVPILNEFAK 
DLYALYPLLIR 
IAELLGMDLASLEITAHNER 7 2 570,723 5.15 194 gi|226386| 
4 
Sarcoplasmic 
reticulum 
calcium 
ATPase 
SERCA1 
FMEYETDLTFVGVVGMLDPPRK 
ISLPVIGLDEILK 2 3 111,780 5.14 81 gi|147903853| 
5 
Calcium-
ATPase, Chain 
DIVPGDIVEVAVGDKVPADIR 
ISLPVIGLDEILK 2 3 110,811 5.15 72  gi|18159010| 
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A, E2 State 
8 
Sarcoplasmic 
reticulum 
calcium 
ATPase 
SERCA1 
FMEYETDLTFVGVVGMLDPPRK 
ISLPVIGLDEILK 2 3 111,780 5.14 63 gi|147903853| 
9 
Calcium-
ATPase, Chain 
A, E2 State 
DIVPGDIVEVAVGDKVPADIR 
ISLPVIGLDEILK 2 3 110,811 5.15 72  gi|18159010| 
10a 
Sarcoplasmic 
reticulum 
calcium 
ATPase 
SERCA1 
DIVPGDIVEVAVGDKVPADIR 
ALGIVATTGVSTEIGK 
EFTLEFSR 
FMEYETDLTFVGVVGMLDPPRK 
IVEYLQSYDEITAMTGDGVNDAPALKK 
TASEMVLADDNFSTIVAAVEEGR 
ALDLTQWLMVLK 
ISLPVIGLDEILK 8 14 111,780 5.14 205 gi|147903853| 
10b 
Sarcoplasmic 
reticulum DIVPGDIVEVAVGDKVPADLR 
2 2 112,101 5.48 38 gi|291405296| 
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calcium 
ATPase 
EFTLEFSR 
11a 
Calcium-
ATPase, Chain 
A, E2 State 
DIVPGDIVEVAVGDKVPADIR 
VDQSILTGESVSVIK 
ALGIVATTGVSTEIGK  
EFTLEFSR 
RIGIFGENEEVADR 
IGIFGENEEVADR 
IVEYLQSYDEITAMTGDGVNDAPALK 
IVEYLQSYDEITAMTGDGVNDAPALKK 
TASEMVLADDNFSTIVAAVEEGR 
ISLPVIGLDEILK 10 13 110,811 5.15 881 gi|18159010| 
11b 
Sarcoplasmic 
reticulum 
calcium 
ATPase 
SERCA1 
DIVPGDIVEVAVGDKVPADIR 
VDQSILTGESVSVIK 
EFTLEFSR 
RIGIFGENEEVADR 
IGIFGENEEVADR 
IVEYLQSYDEITAMTGDGVNDAPALK 
TASEMVLADDNFSTIVAAVEEGR 
8 13 111,780 5.14 881 gi|147903853| 
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ISLPVIGLDEILK 
11c 
Sarcoplasmic 
reticulum 
calcium 
ATPase 
DIVPGDIVEVAVGDKVPADLR 
EFTLEFSR 2 2 112,101 5.48 38 gi|291405296| 
14 Calsequestrin 
EEGLDFPEYDGVDR 
QFEMEELILELAAQVLEDK 
LGLTEEDSIYVFK 3 12 42,407 3.93 162 gi|157829745| 
15 Calsequestrin 
QFEMEELILELAAQVLEDK 
ELQAFENIEDEIK 2 8 42,407 3.93 180 gi|157829745| 
17 
53 kDa SR 
glycoprotein / 
sarcalumenin 
EEISLLEDLNQVIENR 
DFFGINPISSFK 
AITQELPSLLGSLGLGK 3 9 54,764 6.21 167 gi|623545| 
18 
Elongation 
factor 1-alpha 
THINIVVIGHVDSGK 
NIITGTPQDDCAVLIVAAGVGEFEAGIS
K 2 11 40,807 6.83 100 gi|74003751| 
20 
Creatine 
kinase 
NKVTPNGYTLDQCIQTGVDNPGHPFIK 
GTGGVDTAAVADVYDISNIDR 2 11 48,012 8.46 80 gi|338237| 
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23a Aldolase GVVPLAGTDGETTTQGLDGLSER 
TVPPAVTGVTFLSGSEEEEGASINLNAI
NK 
2 14 39,457 9.06 98  gi|229506| 
24 Protein similar 
to C34G6.1  
ETRAFLLSSSPGR 
DDPHSLVALEAMVGLAR 
2 2 164,959 6.37 32 gi|73974872| 
26  ADP/ATP 
translocase 3 
GAWSNILRGMGGAFVLVLYDELKK 
GMGGAFVLVLYDELK 
2 8 33,078 9.73 58 gi|126325903| 
 
*NCBInr Database, release 20100212 
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Table 6.2 List of MS-identified proteins from SR fraction that were identified with one peptide matched. 
Band 
No. Name of identified protein Peptide Sequence 
Peptides 
Matched 
Coverage(
%) kDa pI 
Mascot 
Score Accession No.
* 
2 myosin heavy chain isoform 2b LASADIETYLLEK 1 1 224021 5.6 55  gi|291405035 
6 Nedd4 binding protein 1 FPLLAPLPSIPQNLSMPAQR 1 2 101446 5.72 41 gi|291410221 
7 
sarcoplasmic reticulum 
glycoprotein EEISLLEDLNQVIENR 1 3 54764 6.21 78 gi|623545 
12  phosphofructokinase, muscle LNIIIVAEGAIDR 1 1 94181 7.85 114 gi|291414479 
13 heat shock 70kDa protein 5 IEIESFYEGEDFSETLTR 1 2 72314 5.15 68 gi|291408341 
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21 
 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 10 
LLQYADALEHLLSTGQGVVL
ER 1 6 40716 7.62 51  gi|291414461 
22 
Fructose-bisphosphate aldolase 
A 
YTPSGQAGAAASESLFIPNQA
Y 1 11 20702 5.51 70 gi|73976435 
23 aldolase C 
GVVPLAGTDGETTTQGLDGL
SER 
2 14 39457 9.06 98  gi|229506 
25 
dehydrogenase/reductase (SDR 
family) member 7C  LENLYDALISVADPSK 1 5 35083 8.76 75 gi|291405047 
27 
trimeric intracellular cation 
channel type A  GSGVALLSNVEQLLR 1 5 33265 8.64 90 gi|153792068 
28 
trimeric intracellular cation 
channel type A GSGVALLSNVEQLLR 1 5 33265 8.61 93  gi|153792068 
32 adenylate kinase 1  IAQPTLLLYVDAGPETMK 1 9 21741 8.72 80 gi|291413541 
  122 
33 reticulon 2-like GDGANPFQAYLDVDLTLTR 1 4 50399 4.83 146 gi|291414836 
34 
S100 calcium binding protein, 
zeta-like MPTQLEMAMDTMIRIFHR 1 18 11842 6.1 37 gi|291413610 
35 Nedd4 binding protein 1 FPLLAPLPSIPQNLSMPAQR 1 2 101446 5.72 41  gi|291410221 
 
*NCBInr Database, release 20100212 
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6.2.4 Immunoblot analysis of Ca
2+ 
regulatory proteins of the sarcoplasmic reticulum. 
For comparative purposes and to verify the electrophoretic position of key Ca
2+
-handling 
proteins in one-dimensional gradient gels, immunoblotting of RyR, SERCA, CSQ and SAR 
are shown in Figure 6.3. The main immuno-decorated band for the SR Ca
2+
-release channel 
was shown to be at a molecular mass of approximately 570 kDa (Figure 6.3A), which agrees 
with the position of the protein band that was identified as the RyR1 isoform by on-membrane 
digestion (Figure 6.2, Table 6.1). Interestingly, immuno-labeling with a monoclonal antibody 
to the fast SERCA1 isoform of apparent 112 kDa revealed 3 main bands, probably 
representing monomers, dimers and tetramers (Figure 6.3B). This finding agrees with the fact 
that our MS analysis identified several bands with differing molecular mass as SERCA units 
(Figure 6.3, Table 6.1). Figure 6.3C illustrates antibody labeling of the 63 kDa monomeric 
CSQ protein and this finding is in agreement with the position of the main MS-identified CSQ 
band in gradient gels (Figure 6.3, Table 6.1). Immunoblotting of SAR revealed a labeled 
protein band of approximately 160 kDa (Figure 6.3D). Immunoblotting survey shown in 
Figure 6.3 agrees with the proteomic characterization of the electrophoretically separated SR 
fraction. 
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Figure 6.3 Immunoblot analysis of SR-identified proteins. 
Shown is 1-D immuno-decorated bands and graphical presentation of antibody labelled SR 
proteins, representing RyR (1), Sarcoplasmic/endoplasmic Ca
2+
-ATPase (SERCA) (2), 
calsequestrin (CSQ) (3) and sarcalumenin (SAR) (4).  
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6.3 Discussion 
Two dimensional gels have been instrumental to the birth and development of proteomics 
however it is fair to say that hydrophobic proteins, membrane proteins and low abundance 
proteins are still under represented on 2-D gels. In this study we have used on-membrane 
digestion as a method to detect integral membrane proteins, high-molecular mass proteins and 
components of the rabbit skeletal muscle sarcoplasmic reticulum (SR). The MS-based 
proteomic characterisation of the SR fraction revealed 31 SR-associated protein species. The 
most highly abundant SR protein, SERCA-type Ca
2+
-ATPase (Moller et al. 2010) was found 
to be present in the main 112 kDa band and several other protein bands in the one-
dimensional gel. The other main players involved in Ca
2+
-cycling through the SR, The RyR 
Ca
2+
-release channel (band 1), the Ca
2+
-binding protein CSQ (band 14, 15) and the Ca
2+
-
shuttle element sarcalumenin SAR and its related glycoprotein 53-GP (band 17) were all 
clearly identified by MS analysis. The on-membrane digestion method has clearly identified 
the main ion-regulatory elements involved in the energy-dependent Ca
2+
-release during 
excitation-contraction coupling (Radermacher et al. 1994), Ca
2+
-uptake during muscle 
relaxation (Moller et al. 2010), Ca
2+
-shutting within the longtitudinal SR tubules (Leberer et 
al. 1990) and Ca
2+
-buffering within the lumen of the terminal cisternae region (Royer and 
Rios 2009).  
 
6.3.1 Glycolytic enzymes 
An interesting finding of this MS-based survey of the SR membrane is the identification of 
the glycolytic enzymes to be present in the SR-enriched subcellular fraction. Both aldolase 
(band 23) and phosphofructokinase appear to be physically linked to the SR in rabbit skeletal 
muscle tissue with agrees with previous studies that has demonstrated functional coupling 
between SR Ca
2+
-transport and ATP production via the glycolytic pathway (Xu and Becker 
1998). 
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6.4 Conclusions 
In conclusion the application of subcellular fractionation to reduce sample complexicity and 
the use of one-dimensional gradient gel electrophoresis followed by on-membrane digestion 
and MS analysis has successfully identified a large number of distinct protein species in the 
SR fraction from rabbit skeletal muscle. On-membrane digestion is shown to be a highly 
suitable technique for studying integral and high-molecular-mass muscle proteins in 
subcellular fractions. A high number of muscular disorders are involved with membrane 
proteins for example the chloride channelopathy myotonia congentia. It may be advantageous 
to look at protein complexes that are involved in signal transduction pathways that relate 
muscle membrane hyperexcitability to fiber phenotype. A proteomic study inclusive of high 
molecular weight proteins unable to enter a 2-D gel with sebsequent mass spectrometric 
identificationmay give insight into the proteins involved with controlling muscle fiber 
phenotype. 
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7. General Discussion 
 
Skeletal muscle is an effector organ that transforms potential energy into contractile force and 
movement. This movement allows organisms with a means of reacting to its environment. 
The muscle fibers which make up the tissue are extremely adaptive to numerous external 
cues, from neuromuscular activity and physical activity to several diseased states. 
 
This proteomic study has focused on the biochemical establishment of secondary effects of 
myotonia and denervation on the skeletal muscle proteome. Proteomic profiling resulted in 
the observation of very different fiber type transitions in both diseased states. The long term 
muscle activity in hyperexcitable muscle due to a single gene defect influenced a multitude of 
secondary changes in the skeletal muscle proteome. The proteomic profiling of the myotonic 
animal models ADR, MTO and MTO*5J clearly revealed a drastically  perturbed protein 
expression pattern in the severely affected ADR and MTO muscle, but only moderate changes 
in mildly diseased MTO*5J animals. Hence, the severity of myotonic symptoms appears to 
correlate well with quantitative and qualitative alterations in the protein complement of ADR 
and MTO vs. MTO*5J.  As seen in Figure 7.1 the loss of sarcolemma Cl
-
 conductance 
destabilizes the membrane potential and leads to hyperexcitability of the muscle fiber, the 
hallmark of myotonia. The unscheduled bursts of action potentials cause bursts of 
intracellular Ca
2+
 release and cramps. The muscle cramps experienced with myotonia can lead 
to mechanical stress on the muscle resulting in increased expression of stress proteins. All 
three animal models displayed increases in stress proteins: MTO*5J (Hsp27), MTO (Hsp 7 
and Hsp2), ADR (Hsp 40). The elevated intracellular Ca
2+
 activates Ca
2+
-dependent signalling 
pathways e.g. those involving calmodulin/calcineurin and NFAT (shown in Figure 7.1). 
Activation of these signalling pathways leads to the transcription of the slow gene program. 
This is seen in myotonic muscle where there is a switch of isoforms of contractile proteins 
MHC fast to MHC slow along with reduced levels of MLC2f and phosphorylatable MLC2f. 
The reduced levels of the MHC fast isoform to its slower isoform along with increased levels 
in oxidative phosphorylation enzymes such as cytochrome c in ADR muscle and NADH in 
MTO muscle agrees with the idea of myotonia-induced muscle transformation of both the 
contractile apparatus and muscle metabolism. The findings in chapter 3 and chapter 4 were in 
line with previous studies of muscle transformation after chronic low-frequency stimulation 
(Donoghue et al. 2007). In addition to the common fiber-type specific markers, many other 
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interesting changes occured in the myotonic animal models. Parvalbumin is a soluable Ca
2+
-
binding protein that is present chiefly in the fast-twitch fibers where it plays a role in fast-
twitch relaxation (Muntener et al. 1995; Schwaller et al. 1999).  The decreased expression of 
parvalbumin in all three myotonic skeletal tissues could result in a higher concentration of 
free cytosolic Ca
2+
. As discussed Ca
2+
 plays an important role in Ca
2+
-dependent 
transcriptional pathways e.g. calcineurin. Over expression of parvalbumin in slow fibers 
resulted in faster twitch contraction and increased relxation time in the slow-twitch soleus 
muscle, along with a reduction in calcineurin activity (Chin et al. 2003). These findings 
indicate that parvalbumin expression in fast-twitch fibers act to buffer free cytosolic Ca
2+ 
whereby it could prevent its binding to Ca
2+
-depenpdent pathways such as calcinuerin that 
activate  transcription of  the slow gene program. This is clearly seen in our proteomic 
profiling of skeletal muscle from myotonic mice were expression of slower isoforms of 
contractile proteins are increased along with increased expression of mitochondrial enzymes 
indicative of a slow-twitch fiber phenotype. The varying degree of  decreased expression of 
parvalbumin in ADR and MTO vs. MTO*5J might be used as a reliable general marker of the 
severity of myotonia. Similarly with the protein disulfide isomerase was shown to be 
increased in ADR muscle, but decreased in MTO, and  could potentially be used as a 
differentiating marker of these two different myotonic phenotypes. Further biochemical 
studies are needed to fully interpret the effects of these changes on gene regulation in skeletal 
muscle.  
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Figure 7.1 Overview of the changes seen in Myotonic skeletal tissue. 
Shows an overview of the the changes in myotonic muscle as determined my proteomic 
profiling. Hyperexcitabilty of skeletal muscle leads to unscheduled bursts of action potentials 
resulting in bursts of Ca
2+
 concentration. Increased cytosolic Ca
2+ 
can influence transcription 
patterns through calmodulin/calcineurin signalling. Myotonic muscle shows fiber type 
switching from fast-glycolytic to slow-oxidative fiber phenotype.  
 
The objective to our proteomic profiling study of the WR mouse was the establishment of 
global effects of motor neuron disease on the protein complement from skeletal muscle tissue. 
The most prominent changes in gene expression in muscles affected by motor neuron 
degeneration were expected to reflect physiological denervation. Importantly, the WR 
pathology is a long-term and continuous process, as opposed to surgical denervation, intrinsic 
effects of the partial deficiency in VPS54 cause proteome-wide alterations in skeletal muscle 
as shown in Figure 7.2. Following differential fluorescent tagging, gel electrophoretic 
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separation, densitometric scanning and image analysis, 24 protein spots were identified in WR 
muscle tissue that exhibit a significant change in concentration levels. Expression levels were 
reduced in the case of 3 protein species and increased for 21 proteins. In contrast to myotonic 
mouse muscle, in which there is a shift from the dominant myosin heavy chain (MHC) 
isoform IIB to IIX and IIA , in WR muscle there is an opposite shift to an even higher 
proportion of MHC IIB and a glycolytic phenotype. The highest increases in WR muscle was 
found for the glycolytic enzyme aldolase followed by GAPDH. These two enzymes with an 
increased concentration reflect a shift towards an extreme glycolytic muscle fiber type. 
Similar to myotonic muscle the skeletal tissue from the WR mouse showed a significant 
decrease in the Ca
2+
-binding protein parvalbumin. It is interesting that the WR skeletal muscle 
shows a shift towards glycolytic metabolism indicative of fast-twitch fibers yet they have 
decreased expression of parvalbumin at the mRNA level (Sedehizade et al. 1997) and protein 
level (Staunton et al. 2011).  Perhaps this protein could be used as a biomarker for both 
muscle excitabiltiy and motor neuron degeneration in skeletal muscle. Both diseases show 
drastic fiber type switiching yet a similar decrease in the Ca
2+
-binding protein parvalbumin.  
 Future work is needed to determine the signalling pathways involved in fiber type switching 
in order to gain a better understanding of Ca
2+
- dependent signalling pathways that determine 
gene expression in fast-twitch and slow-twitch muscle. Perhaps the use of muscle cell lines 
e.g. C2C12 (Kane et al. 2009) could be used to further understand the cellular signalling 
pathways that control fiber-specific genes.  
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Figure 7.2 Overview of changes observed in the Wobbler skeletal tissue. 
Shows the overall changes observed in the Wobbler skeletal tissue. The destabilisation of 
Vsp54 protein leads to a reduced concentration of the GARP complex resulting in motor 
neuron degeneration and impaired spermiogenesis in the Wobbler mouse. Muscle denervation 
results in fiber type switching from slow oxidative to fast glycolytic fiber phenotype. The 
proteomic profiling from the Wobbler skeletal tissue shows a drastic increase in glycolytic 
enzymes along with increases in the fast MLC of the contractile apparatus. 
 
Proteomic studies have shown that mass spectrometry-based technologies can be used for 
studying a representative proportion of muscle proteins involved in contraction, metabolism, 
cellular stress response or calcium regulation. However, there are limitations to this method 
with respect to studying the entire proteome. High molecular weight proteins, membrane 
proteins and low abundance proteins can be difficult to detect in polyacrylamide gels due to 
pore size, hydrophobic nature and dynamic range. A mulitude of approaches have been 
attempted in order resolve these problems, from gel-free approaches or shot gun proteomics. 
In chapter 6 we attempted to optimise the on-membrane digestion of SR-associated proteins. 
Since the abundant SR membrane system plays a key role in excitation-contraction-relaxation 
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cycles and because SR proteins are involved in numerous human diseases (MacLennan et al. 
2011), the establishment of a complete list of SR-associated proteins will be extremely useful 
for the evaluation of novel biomarker signatures of neuromuscular disorders and the 
identification of new therapeutic targets to treat channelopathies.  
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